Background:

Sugar-sweetened beverage (SSB) consumption may be associated with cancer mortality independent of, or indirectly through, established influences on increased body adiposity.

Methods:

We examined the associations of SSBs and artificially-sweetened beverages (ASB) with mortality from all-cancers combined, obesity-related cancers combined, and 20 cancer types, among men and women in the Cancer Prevention Study-II (CPS-II) prospective cohort. In 1982, 934,777 cancer-free participants provided information on usual SSB and ASB consumption. Deaths were identified through 2016. Multivariable Cox proportional hazards regression models examined associations of beverage types with cancer mortality, without and with BMI adjustment.

Results:

During follow-up, 135,093 CPS-II participants died from cancer. Consumption of ≥2 SSB drinks/day vs. never was not associated with all-cancer mortality, but was associated with increased risk of obesity-related cancers [HR, 1.05; 95% confidence intervals (CI), 1.01–1.08; Ptrend = 0.057], which became null after adjustment for BMI. SSBs were associated with increased mortality from colorectal (HR, 1.09; 95% CI, 1.02–1.17; Ptrend = 0.011), and kidney (HR, 1.17; 95% CI, 1.03–1.34; Ptrend = 0.056) cancers, which remained after BMI adjustment. A positive association of ASB consumption with obesity-related cancers (HR, 1.05; 95% CI, 1.01–1.08; Ptrend = 0.001) was null after controlling for BMI; however, an increased risk of pancreatic cancer was robust to BMI adjustment (HR, 1.11; 95% CI, 1.02–1.20; Ptrend < 0.008).

Conclusions:

SSB consumption was associated with higher mortality from certain cancers, partially mediated through obesity. Associations of ASB consumption and increased pancreatic cancer risk merit further study.

Impact:

Future research should consider the role of BMI in studies of sweetened beverages and cancer risk. These results should inform policy regarding sweetened beverage consumption.

In the United States, sugar-sweetened beverages (SSB) are the top contributors to added sugar in the diet (1, 2), and approximately 50% of adults consume one serving or more on any given day (3). Although energy and added sugar intake from SSBs decreased from 2003/2004 to 2015/2016 (4), approximately 60% of adults still exceed the 10% limits of total energy from sugar advised in the US Dietary Guidelines (1). In contrast, artificially-sweetened beverage (ASB) consumption increased in U.S. adults from 1999/2000 to 2009/2010 from 17.8% to 21.2% for females and from 13.9% to 19.0% for males (5, 6), with more recent consumption prevalence estimates from 2009 to 2012 NHANES of 34% and 28% in women and men, respectively (7).

The evidence that sugary drinks increase the risk of weight gain, overweight, and obesity is well established (8) from both randomized controlled trials and meta-analyses of prospective studies of weight change (9). Compared with calories as part of a solid meal, the extra calories consumed in soft drinks are not typically offset by reductions from other sources. SSB consumption may therefore increase cancer risk or mortality via excess body fatness, which is strongly related to several cancer types (10). Carcinogenic mechanisms potentially related to SSBs, both through—and independent of—body weight, involve perturbations of glucose and insulin homeostasis, inflammation and oxidative stress, and location of body fat (e.g., visceral adiposity; refs. 8, 11–15). Although generally not considered causally associated with weight gain (with some exceptions; refs. 16–18, 19), ASB consumption is higher in overweight and obese individuals, among whom calories saved may be compensated with solid food intake (20). Provocative data in mice suggest that alteration of the gut microbiome with artificial sweetener consumption may lead to metabolic disturbances (21–24), although a trial of aspartame or sucralose in humans showed minimal impact on human gut microbiota composition (25). Artificial sweeteners may also influence insulin resistance (26) and inflammation (27), but most available data in humans are from small and relatively short-term studies.

A growing number of epidemiologic studies have comprehensively examined SSB and ASB consumption in relation to incidence or mortality from all cancers or obesity-related cancers combined. In three of seven (28–34) prospective cohort studies, SSBs were associated with increased cancer-related mortality (28) or cancer incidence (29, 33). Two (28, 29) reported positive associations even after controlling for BMI, suggesting a BMI-independent role of SSBs in carcinogenesis, and in one, BMI was presumed to be in the causal pathway and thus not included in the statistical models (33). Associations of ASBs with these cancer outcomes were mostly null (28–30, 32, 33). Although generally regarded as safe by regulatory agencies worldwide, whether artificial sweeteners may promote development of cancer is controversial (35, 36), highlighting the need to examine associations of ASBs and cancer outcomes.

For individual cancers, a recent meta-analysis of 27 observational studies found significant associations between SSB intake and breast and prostate cancers, and positive associations with colorectal and pancreatic cancers; for ASB consumption, the study found a suggestion of increased risk for pancreatic cancer (37). Data are sparse and inconsistent for other cancers (37).

We examined associations of SSB and ASB consumption with mortality from all cancers combined, obesity-related cancers combined, and with 20 individual cancer types, in a large, prospective cohort of U.S. men and women. Associations were examined without and with statistical adjustment for BMI, and for both sexes separately and combined.

Study population

In 1982, 1,184,284 men and women ages 28 years or older were enrolled by American Cancer Society (ACS) volunteers in all 50 states, the District of Columbia and Puerto Rico into the Cancer Prevention Study-II (CPS-II; ref. 38), a prospective cohort study designed to examine risk factors for cancer mortality. At baseline, participants completed a 4-page confidential questionnaire on medical history and demographic and lifestyle exposures. Informed consent to participate in the study was implied by return of the self-administered questionnaire. The study was conducted in accordance with recognized ethical standards (e.g., Declaration of Helsinki). All aspects of the CPS-II study have been approved by the Institutional Review Board of Emory University.

Participants were excluded from this analysis if they had a personal history of cancer at baseline other than nonmelanoma skin cancer (n = 75,708), provided no information on consumption of any beverage type (n = 28,709), reported uninterpretable or potentially erroneous (>10 drinks/day) beverage intakes for SSBs or ASBs (n = 6,583), were men older than age 90 or women older than 95 at enrollment (n = 672; ref. 39), had diabetes at baseline to limit potential biases for diabetes-related cancers (n = 45,562), or reported only prior but not current consumption of either SSBs or ASBs (n = 92,273). This left 416,313 men and 518,464 women in the analytic cohort (total n = 934,777).

Assessment of SSB and ASB consumption

The baseline questionnaire included a grid that asked: “How many cups, glasses, or drinks of these beverages do you usually drink a day, and for how many years?”, with write-in reporting by frequency and duration. “Diet soda or diet iced teas” were considered ASBs, whereas “nondiet colas” and “other nondiet soft drinks” were considered SSBs. Participants were instructed to record “1/2” if they consumed the beverage less than once a day, but at least three times a week. If participants reported a change in consumption during the 10 years prior to enrollment, they were asked to record their previous intake of each beverage type. Never drinkers of SSBs and ASBs were defined as participants who wrote zero or left blank their current and previous consumption. Former drinkers who wrote zero or left blank the current intake amount and provided a non-zero amount for previous intake, were excluded as above.

Mortality outcomes

Cause of death was obtained for 99.3% of all known deaths in CPS-II. From 1982 to 1988, cause of death was ascertained by personal inquiries made by volunteers to participants, which were verified by obtaining death certificates. From 1989 through end of follow-up on December 31, 2016, vital status and cause of death were obtained via linkage to the National Death Index (NDI). For this analysis, the outcomes of interest were underlying causes of death from all cancers combined [International Classification of Disease (ICD)-9 codes 140–209; ICD-10 codes C00–C97)], obesity-related cancers combined [esophagus (C15), stomach (C16), colorectum (C18–C21), liver (C22), gallbladder (C23–C24), pancreas (C25), post-menopausal breast (C50), uterus/endometrium (C54–C55), ovary (C56), kidney (C64–C66, C68), and multiple myeloma (C88, C90)], and from 20 specific cancer types where ≥25 deaths had accrued in the highest category of consumption (ICD codes: leukemia (C91–95), non-Hodgkin lymphoma (C96), brain (C70–C72), melanoma (C43), bladder (C67), prostate (C61), small intestine (C17), lung (C33–C34), and larynx/oral cavity/pharynx (C01–C14, C32), in addition to those listed in obesity-related cancers above). Women who reported hysterectomy (n = 132,292), uterine surgery (n = 6,056), or surgically induced menopause (n = 31,803) were excluded from uterine cancer mortality analyses; ovarian cancer mortality analyses additionally excluded women who reported a history of oophorectomy (n = 10,162). Breast cancer mortality models were restricted to post-menopausal women (n = 367,978) at baseline.

Statistical analyses

Follow-up time was calculated from completion of the baseline questionnaire until date of death or December 31, 2016, whichever came first. We censored follow-up at age 90 years for men and 95 years for women to limit potential bias from person-time of older individuals who died but did not link with the NDI (39). Cox proportional hazards models computed HRs and 95% confidence intervals (CI) for associations of SSB and ASB consumption with risk of cancer-related death, using categorical [never (ref), <1 drink/day, 1 drink/day, ≥2 drinks/day] and continuous (per 1 drink/day) exposures. All Cox models were stratified on single year of age, and adjusted for sex in sex-combined models. HRs were additionally adjusted for race/ethnicity, smoking, marital status, education, red and processed meat consumption, fruit and vegetable consumption, and alcohol consumption (categories defined in Table 1 and footnotes to Table 2). Missing data, ranging from 1% to 6% for most covariates, 9% for dietary variables and estrogen use and 17.5% for alcohol, were modeled using a missing indicator variable. SSB and ASB consumption were mutually-adjusted (drinks/day). Among women, analyses of breast (postmenopausal), ovarian, and uterine cancer mortality additionally included parity, age at menarche, estrogen use, oral contraceptive use, and age at first live birth; ovarian and uterine cancer mortality analyses additionally included menopausal status. Aspirin use, multivitamin use, physical activity, and family history of cancer were not included in the final models because of observed minimal impacts on the HRs. BMI (kg/m2) was modeled as a categorical variable, with the top and bottom 0.1% extremes (<15 and ≥46.4) set to missing (<18.5; 18.5–<22.5; 22.5–<25; 25–<27.5; 27.5–<30; 30–<35; 35+; missing). Sensitivity analyses: (i) excluded the first 2 years of follow-up, (ii) restricted the analysis to never-smokers, and (iii) stratified by BMI category [normal weight (18.5–<25), overweight (25–<30), obese (≥30), adjusting for continuous BMI within categories].

Table 1.

Age- and sex-adjusted baseline characteristics according to SSB and ASB consumption in the CPS-II cohorta.

Sugar-sweetenedArtificially-sweetened
Never<1 drink/day1 drink/day2+ drinks/dayNever<1 drink/day1 drink/day2+ drinks/day
Characteristic(n = 626,704)(n = 174,876)(n = 67,833)(n = 65,364)(n = 687,736)(n = 108,594)(n = 71,542)(n = 66,905)
Sugar-sweetened (drinks/day)b 0 (0) 0.5 (0) 1.0 (0) 3.1 (1.6) 0.4 (0.9) 0.3 (0.6) 0.3 (0.6) 0.4 (1.1) 
Artificially-sweetened (drinks/day)b 0.4 (1.0) 0.3 (0.7) 0.3 (0.7) 0.4 (1.1) 0 (0) 0.5 (0) 1.0 (0) 3.1 (1.6) 
Age (years) 57.9 55.1 54.0 52.5 57.6 55.2 53.9 53.0 
Sex (%) 
 Women 58.1 55.2 44.4 43.0 50.8 70.0 66.3 65.1 
 Men 41.9 44.8 55.6 57.0 49.2 30.0 33.7 34.9 
Race (%) 
 White 94.2 93.3 93.0 90.3 93.1 94.8 95.7 95.7 
 Black 3.6 4.4 4.7 7.0 4.4 3.3 2.8 2.8 
 Other/unknownc 2.2 2.3 2.3 2.8 2.5 1.9 1.6 1.6 
Family history of cancer (%) 
 No 60.8 59.8 60.7 61.4 60.9 59.7 60.6 60.7 
 Yes 39.2 40.2 39.3 38.6 39.1 40.3 39.4 39.3 
Smoking status (%)         
 Never smoker 42.9 48.7 46.4 44.4 44.3 45.9 44.8 41.8 
 Former, 20+ years since quit 9.1 9.4 8.5 7.9 8.7 10.6 10.3 9.6 
 Former, 10–<20 years since quit 9.7 9.0 8.0 7.9 8.4 11.6 12.3 11.8 
 Former, <10 years since quit 8.6 7.7 7.6 7.3 7.6 9.3 10.0 10.4 
 Former, unknown years 0.7 0.6 0.6 0.6 0.7 0.8 0.8 0.8 
 Current, <20 CPD 6.8 6.4 7.2 7.6 7.1 5.9 6.0 6.2 
 Current, 20–<40 CPD 10.7 9.4 11.5 12.5 11.9 7.0 7.0 8.6 
 Current, 40+ CPD 3.5 2.7 3.4 4.4 3.7 2.1 2.1 3.2 
 Current, unknown CPD 1.5 1.1 1.2 1.4 1.5 1.1 1.1 1.3 
 Missing/unknown 6.4 4.9 5.5 6.0 6.1 5.7 5.7 6.2 
Body mass index (kg/m225.1 25.3 25.3 25.7 24.8 25.9 26.0 26.5 
Body mass index (kg/m2) (%) 
 15–<18.5 1.8 1.6 2.0 2.0 2.2 0.9 0.8 0.9 
 18.5–<22.5 24.4 22.8 23.0 20.5 26.5 18.0 17.2 15.4 
 22.5–<25 26.5 26.2 25.0 23.7 26.4 25.3 24.7 22.7 
 25–<27.5 24.5 25.3 24.6 24.6 23.7 27.1 27.2 26.3 
 27.5–<30 11.1 11.8 12.0 12.9 10.4 14.0 14.5 15.6 
 30–<35 7.6 8.2 8.8 10.5 6.9 10.0 10.9 12.9 
 35+ 1.7 2.0 2.1 3.1 1.6 2.5 2.6 3.7 
 Missing 2.5 2.2 2.4 2.7 2.4 2.2 2.2 2.5 
Alcohol consumption (%) 
 Nondrinker 50.0 50.0 58.3 56.9 52.6 44.3 49.4 51.3 
 Former drinker 11.7 17.0 9.7 8.8 11.6 17.9 12.5 10.6 
 <1 drink/day 5.9 4.4 6.3 4.0 5.6 4.7 7.3 4.4 
 1 drink/day 13.5 7.8 10.0 11.4 12.1 9.5 12.0 13.3 
 2+ drinks/day 1.1 1.8 1.7 2.3 1.3 1.6 1.7 2.2 
 Missing/unknown 17.7 19.0 14.0 16.5 16.8 22.0 17.1 18.2 
Daily exercise intensity level (%) 
 None 2.1 1.8 2.4 2.7 2.0 2.0 2.2 2.6 
 Slight 22.0 23.2 24.0 23.8 21.6 23.6 25.5 25.3 
 Moderate 65.6 65.7 63.6 61.8 65.8 65.8 63.6 62.2 
 Heavy 8.8 7.9 8.8 10.4 9.0 7.4 7.6 8.6 
 Missing/unknown 1.5 1.3 1.2 1.3 1.6 1.3 1.1 1.2 
Highest education level (%) 
 Less than high school 14.0 13.1 15.2 17.8 15.2 10.7 10.4 11.8 
 High school grad 25.6 26.1 28.1 28.3 26.8 24.0 23.9 25.4 
 Some college/trade school 28.2 29.5 28.8 28.7 28.0 30.0 29.4 29.6 
 College graduate 16.4 16.1 14.6 12.8 15.5 17.6 18.2 16.6 
 Graduate school 14.4 14.3 12.3 11.2 13.1 16.6 17.1 15.4 
 Missing/unknown 1.4 1.0 1.1 1.2 1.3 1.1 1.0 1.3 
Estrogen use (%)d 
 Never users 56.6 57.4 58.1 57.5 57.6 55.2 56.1 54.5 
 Current 8.6 9.2 8.2 8.1 8.3 9.6 9.5 9.1 
 Former 17.1 18.5 17.4 17.0 16.7 19.3 18.5 18.9 
 Missing/unknown 17.7 14.8 16.3 17.5 17.4 16.0 15.9 17.5 
Menopausal status (%)d 
 Pre-menopausal 19.2 19.2 19.4 18.5 19.1 19.4 19.5 18.5 
 Peri-menopausal 7.4 7.6 7.4 7.4 7.3 7.7 7.5 7.6 
 Post-menopausal 71.0 70.9 70.6 71.3 71.1 70.6 70.6 71.1 
 Unknown 2.5 2.3 2.6 2.8 2.5 2.4 2.4 2.7 
Vegetable and fruit (svgs/day) 2.6 2.6 2.4 2.4 2.5 2.7 2.8 2.7 
Red and processed meat (svgs/day) 1.0 1.1 1.2 1.2 1.0 1.0 1.0 1.0 
Caffeinated coffee (cups/day) 2.7 2.4 2.3 2.4 2.6 2.4 2.4 2.5 
Decaffeinated coffee (cups/day) 1.5 1.1 1.1 1.2 1.3 1.4 1.5 1.8 
Sugar-sweetenedArtificially-sweetened
Never<1 drink/day1 drink/day2+ drinks/dayNever<1 drink/day1 drink/day2+ drinks/day
Characteristic(n = 626,704)(n = 174,876)(n = 67,833)(n = 65,364)(n = 687,736)(n = 108,594)(n = 71,542)(n = 66,905)
Sugar-sweetened (drinks/day)b 0 (0) 0.5 (0) 1.0 (0) 3.1 (1.6) 0.4 (0.9) 0.3 (0.6) 0.3 (0.6) 0.4 (1.1) 
Artificially-sweetened (drinks/day)b 0.4 (1.0) 0.3 (0.7) 0.3 (0.7) 0.4 (1.1) 0 (0) 0.5 (0) 1.0 (0) 3.1 (1.6) 
Age (years) 57.9 55.1 54.0 52.5 57.6 55.2 53.9 53.0 
Sex (%) 
 Women 58.1 55.2 44.4 43.0 50.8 70.0 66.3 65.1 
 Men 41.9 44.8 55.6 57.0 49.2 30.0 33.7 34.9 
Race (%) 
 White 94.2 93.3 93.0 90.3 93.1 94.8 95.7 95.7 
 Black 3.6 4.4 4.7 7.0 4.4 3.3 2.8 2.8 
 Other/unknownc 2.2 2.3 2.3 2.8 2.5 1.9 1.6 1.6 
Family history of cancer (%) 
 No 60.8 59.8 60.7 61.4 60.9 59.7 60.6 60.7 
 Yes 39.2 40.2 39.3 38.6 39.1 40.3 39.4 39.3 
Smoking status (%)         
 Never smoker 42.9 48.7 46.4 44.4 44.3 45.9 44.8 41.8 
 Former, 20+ years since quit 9.1 9.4 8.5 7.9 8.7 10.6 10.3 9.6 
 Former, 10–<20 years since quit 9.7 9.0 8.0 7.9 8.4 11.6 12.3 11.8 
 Former, <10 years since quit 8.6 7.7 7.6 7.3 7.6 9.3 10.0 10.4 
 Former, unknown years 0.7 0.6 0.6 0.6 0.7 0.8 0.8 0.8 
 Current, <20 CPD 6.8 6.4 7.2 7.6 7.1 5.9 6.0 6.2 
 Current, 20–<40 CPD 10.7 9.4 11.5 12.5 11.9 7.0 7.0 8.6 
 Current, 40+ CPD 3.5 2.7 3.4 4.4 3.7 2.1 2.1 3.2 
 Current, unknown CPD 1.5 1.1 1.2 1.4 1.5 1.1 1.1 1.3 
 Missing/unknown 6.4 4.9 5.5 6.0 6.1 5.7 5.7 6.2 
Body mass index (kg/m225.1 25.3 25.3 25.7 24.8 25.9 26.0 26.5 
Body mass index (kg/m2) (%) 
 15–<18.5 1.8 1.6 2.0 2.0 2.2 0.9 0.8 0.9 
 18.5–<22.5 24.4 22.8 23.0 20.5 26.5 18.0 17.2 15.4 
 22.5–<25 26.5 26.2 25.0 23.7 26.4 25.3 24.7 22.7 
 25–<27.5 24.5 25.3 24.6 24.6 23.7 27.1 27.2 26.3 
 27.5–<30 11.1 11.8 12.0 12.9 10.4 14.0 14.5 15.6 
 30–<35 7.6 8.2 8.8 10.5 6.9 10.0 10.9 12.9 
 35+ 1.7 2.0 2.1 3.1 1.6 2.5 2.6 3.7 
 Missing 2.5 2.2 2.4 2.7 2.4 2.2 2.2 2.5 
Alcohol consumption (%) 
 Nondrinker 50.0 50.0 58.3 56.9 52.6 44.3 49.4 51.3 
 Former drinker 11.7 17.0 9.7 8.8 11.6 17.9 12.5 10.6 
 <1 drink/day 5.9 4.4 6.3 4.0 5.6 4.7 7.3 4.4 
 1 drink/day 13.5 7.8 10.0 11.4 12.1 9.5 12.0 13.3 
 2+ drinks/day 1.1 1.8 1.7 2.3 1.3 1.6 1.7 2.2 
 Missing/unknown 17.7 19.0 14.0 16.5 16.8 22.0 17.1 18.2 
Daily exercise intensity level (%) 
 None 2.1 1.8 2.4 2.7 2.0 2.0 2.2 2.6 
 Slight 22.0 23.2 24.0 23.8 21.6 23.6 25.5 25.3 
 Moderate 65.6 65.7 63.6 61.8 65.8 65.8 63.6 62.2 
 Heavy 8.8 7.9 8.8 10.4 9.0 7.4 7.6 8.6 
 Missing/unknown 1.5 1.3 1.2 1.3 1.6 1.3 1.1 1.2 
Highest education level (%) 
 Less than high school 14.0 13.1 15.2 17.8 15.2 10.7 10.4 11.8 
 High school grad 25.6 26.1 28.1 28.3 26.8 24.0 23.9 25.4 
 Some college/trade school 28.2 29.5 28.8 28.7 28.0 30.0 29.4 29.6 
 College graduate 16.4 16.1 14.6 12.8 15.5 17.6 18.2 16.6 
 Graduate school 14.4 14.3 12.3 11.2 13.1 16.6 17.1 15.4 
 Missing/unknown 1.4 1.0 1.1 1.2 1.3 1.1 1.0 1.3 
Estrogen use (%)d 
 Never users 56.6 57.4 58.1 57.5 57.6 55.2 56.1 54.5 
 Current 8.6 9.2 8.2 8.1 8.3 9.6 9.5 9.1 
 Former 17.1 18.5 17.4 17.0 16.7 19.3 18.5 18.9 
 Missing/unknown 17.7 14.8 16.3 17.5 17.4 16.0 15.9 17.5 
Menopausal status (%)d 
 Pre-menopausal 19.2 19.2 19.4 18.5 19.1 19.4 19.5 18.5 
 Peri-menopausal 7.4 7.6 7.4 7.4 7.3 7.7 7.5 7.6 
 Post-menopausal 71.0 70.9 70.6 71.3 71.1 70.6 70.6 71.1 
 Unknown 2.5 2.3 2.6 2.8 2.5 2.4 2.4 2.7 
Vegetable and fruit (svgs/day) 2.6 2.6 2.4 2.4 2.5 2.7 2.8 2.7 
Red and processed meat (svgs/day) 1.0 1.1 1.2 1.2 1.0 1.0 1.0 1.0 
Caffeinated coffee (cups/day) 2.7 2.4 2.3 2.4 2.6 2.4 2.4 2.5 
Decaffeinated coffee (cups/day) 1.5 1.1 1.1 1.2 1.3 1.4 1.5 1.8 

Abbreviations: svgs, servings; CPD, cigarettes per day.

aAll population characteristics are age and sex-adjusted, except for age (only sex-adjusted), sex (only age-adjusted). Mean values are presented unless otherwise indicated.

bMeans (SD) of SSB and ASB intake.

c“Other” refers to selecting Asian, Hispanic, or a write-in for “Other.”

dPercentages shown are among women only.

Table 2.

Associations (HR, 95% CI) of SSB consumption and all-cancer and site-specific cancer mortality in CPS II, 1982–2016.

SSB consumptionaContinuousb
Cancer site/typeDeathsPerson yearsNever (ref)<1 drink/day1 drink/day2+ drinks/dayPtrendPer 1 drink/dayP valuePinteraction
All cancers          <0.0001 
 Men 70,834 1,226,073 1.00 0.98 (0.96–1.00) 0.96 (0.94–0.99) 0.99 (0.96–1.02) 0.073 1.00 (0.99–1.00) 0.356  
 Women 64,259 1,188,795 1.00 0.98 (0.96–1.00) 1.01 (0.98–1.04) 1.01 (0.98–1.05) 0.807 1.00 (0.99–1.01) 0.352  
 Combined 135,093 2,414,868 1.00 0.98 (0.96–0.99) 0.98 (0.95–1.00) 0.99 (0.97–1.01) 0.061 1.00 (0.99–1.00) 0.462  
Obesity-related cancersc          0.311 
 Men 20,595 351,011 1.00 0.98 (0.95–1.02) 0.98 (0.94–1.03) 1.06 (1.01–1.12) 0.082 1.02 (1.00–1.03) 0.033  
 Women 30,018 542,434 1.00 1.00 (0.97–1.03) 1.02 (0.97–1.07) 1.03 (0.97–1.08) 0.268 1.01 (1.00–1.03) 0.101  
 Combined 50,613 893,445 1.00 0.99 (0.97–1.02) 1.00 (0.97–1.04) 1.05 (1.01–1.08) 0.057 1.01 (1.00–1.02) 0.009  
Larynx/oral cavity/pharynx (C01-C14, C32)          0.366 
 Men 1,215 19,894 1.00 0.78 (0.66–0.93) 1.04 (0.85–1.27) 0.99 (0.81–1.22) 0.781 1.00 (0.94–1.06) 0.964  
 Women 637 11,796 1.00 0.93 (0.75–1.17) 0.85 (0.59–1.22) 1.20 (0.87–1.65) 0.621 1.05 (0.96–1.15) 0.257  
 Combined 1,852 31,691 1.00 0.83 (0.73–0.95) 0.98 (0.82–1.17) 1.04 (0.87–1.24) 0.963 1.01 (0.97–1.06) 0.607  
Esophageal (C15)          0.317 
 Mend 2,080 37,313 1.00 0.96 (0.85–1.08) 0.81 (0.68–0.95) 0.90 (0.76–1.05) 0.038 0.97 (0.92–1.01) 0.158  
 Women 647 12,829 1.00 0.91 (0.74–1.13) 0.83 (0.57–1.20) 0.77 (0.51–1.15) 0.100 0.94 (0.84–1.05) 0.269  
 Combined 2,727 50,142 1.00 0.95 (0.86–1.05) 0.82 (0.70–0.95) 0.88 (0.76–1.03) 0.016 0.97 (0.92–1.01) 0.108  
Stomach (C16)          0.967 
 Men 1,716 25,184 1.00 0.86 (0.75–0.98) 1.20 (1.02–1.41) 1.14 (0.96–1.35) 0.074 1.04 (0.99–1.09) 0.126  
 Women 1,082 18,213 1.00 1.00 (0.85–1.18) 1.17 (0.91–1.51) 0.95 (0.71–1.27) 0.841 1.03 (0.96–1.11) 0.371  
 Combined 2,798 43,397 1.00 0.91 (0.82–1.01) 1.19 (1.04–1.37) 1.08 (0.94–1.25) 0.128 1.03 (0.99–1.08) 0.089  
Liver (C22)          0.763 
 Men 1,576 30,433 1.00 1.04 (0.91–1.19) 0.97 (0.81–1.17) 1.06 (0.89–1.27) 0.589 1.02 (0.97–1.08) 0.345  
 Women 1,146 23,971 1.00 0.99 (0.85–1.16) 0.86 (0.66–1.13) 1.13 (0.88–1.45) 0.700 1.02 (0.95–1.10) 0.520  
 Combined 2,722 54,404 1.00 1.02 (0.92–1.12) 0.93 (0.80–1.08) 1.07 (0.92–1.24) 0.648 1.02 (0.98–1.06) 0.340  
Pancreas (C25)          0.220 
 Men 4,339 76,644 1.00 1.00 (0.92–1.08) 0.98 (0.88–1.09) 1.09 (0.98–1.22) 0.223 1.01 (0.98–1.04) 0.499  
 Women 4,857 93,975 1.00 1.00 (0.92–1.08) 1.03 (0.91–1.17) 0.91 (0.79–1.05) 0.343 0.99 (0.95–1.03) 0.570  
 Combined 9,196 170,619 1.00 0.99 (0.94–1.05) 1.00 (0.92–1.08) 1.02 (0.94–1.11) 0.754 1.00 (0.98–1.03) 0.864  
Gall bladder (C23–24)          0.722 
 Men 378 6,430 1.00 1.38 (1.06–1.78) 1.44 (1.03–2.02) 1.05 (0.7–1.57) 0.218 1.04 (0.94–1.15) 0.499  
 Women 646 10,874 1.00 1.19 (0.98–1.46) 1.07 (0.76–1.52) 1.24 (0.88–1.74) 0.121 1.03 (0.94–1.14) 0.478  
 Combined 1,024 17,304 1.00 1.26 (1.07–1.47) 1.23 (0.97–1.56) 1.13 (0.87–1.47) 0.060 1.03 (0.96–1.11) 0.370  
Lung (C33–34)          0.005 
 Men 20,121 327,494 1.00 0.90 (0.87–0.94) 0.91 (0.86–0.96) 0.90 (0.85–0.94) <0.0001 0.97 (0.96–0.99) <0.0001  
 Women 14,260 265,675 1.00 0.89 (0.85–0.93) 0.97 (0.90–1.04) 0.95 (0.88–1.02) 0.011 0.99 (0.97–1.01) 0.163  
 Combined 34,381 593,169 1.00 0.90 (0.87–0.92) 0.93 (0.89–0.97) 0.91 (0.87–0.95) <0.0001 0.98 (0.96–0.99) <0.0001  
Small intestine (C17)          N/A 
 Combined 324 5,749 1.00 0.95 (0.71–1.28) 0.76 (0.47–1.23) 1.26 (0.84–1.90) 0.609 1.01 (0.89–1.14) 0.899  
Colorectal (C18–21)          0.384 
 Men 6,660 105,640 1.00 1.00 (0.94–1.07) 1.00 (0.91–1.09) 1.09 (1.00–1.19) 0.109 1.02 (0.99–1.04) 0.164  
 Women 7,092 123,386 1.00 0.97 (0.91–1.04) 1.15 (1.04–1.27) 1.09 (0.98–1.21) 0.035 1.03 (1.00–1.06) 0.046  
 Combined 13,752 229,025 1.00 0.99 (0.94–1.03) 1.06 (0.99–1.13) 1.09 (1.02–1.17) 0.011 1.02 (1.00–1.04) 0.021  
Breaste (C50)          N/A 
 Women, post-menopausal 6,074 104,596 1.00 0.98 (0.92–1.05) 1.01 (0.90–1.13) 1.05 (0.93–1.19) 0.558 1.00 (0.96–1.03) 0.835  
Uteruse,f (C54-C55)          N/A 
 Women 1,693 31,754 1.00 1.09 (0.96–1.23) 1.00 (0.80–1.23) 1.17 (0.95–1.45) 0.136 1.04 (0.98–1.11) 0.148  
Ovarye,f (C56)          N/A 
 Women 3,225 56,993 1.00 1.05 (0.95–1.14) 0.91 (0.77–1.06) 0.99 (0.84–1.17) 0.761 1.01 (0.97–1.06) 0.656  
Prostate (C61)          N/A 
 Men 9,381 171,583 1.00 1.01 (0.95–1.06) 0.91 (0.84–0.98) 1.01 (0.93–1.09) 0.570 0.99 (0.97–1.01) 0.299  
Kidney (C64-C66, C68)          0.385 
 Men 1,921 33,276 1.00 0.99 (0.87–1.11) 0.95 (0.81–1.12) 1.13 (0.96–1.32) 0.278 1.05 (1.01–1.10) 0.022  
 Womend 1,208 22,086 1.00 1.06 (0.91–1.23) 0.99 (0.76–1.27) 1.29 (1.02–1.64) 0.063 1.09 (1.02–1.16) 0.008  
 Combined 3,129 55,363 1.00 1.01 (0.92–1.11) 0.97 (0.84–1.11) 1.17 (1.03–1.34) 0.056 1.06 (1.02–1.10) 0.001  
Bladder (C67)          0.535 
 Men 2,431 48,116 1.00 1.06 (0.95–1.18) 1.12 (0.97–1.29) 1.13 (0.97–1.31) 0.041 1.04 (1.00–1.08) 0.071  
 Women 988 20,179 1.00 1.01 (0.85–1.19) 1.02 (0.76–1.35) 1.07 (0.79–1.43) 0.686 0.99 (0.91–1.08) 0.811  
 Combined 3,419 68,295 1.00 1.04 (0.95–1.14) 1.09 (0.96–1.24) 1.11 (0.97–1.27) 0.050 1.03 (0.99–1.07) 0.146  
Melanoma (C43)          0.209 
 Men 1,412 26,399 1.00 1.07 (0.94–1.23) 1.14 (0.96–1.37) 0.84 (0.68–1.04) 0.491 0.96 (0.90–1.02) 0.156  
 Women 718 13,946 1.00 1.06 (0.87–1.28) 1.07 (0.78–1.47) 1.02 (0.72–1.45) 0.695 1.01 (0.92–1.12) 0.793  
 Combined 2,130 40,346 1.00 1.07 (0.95–1.19) 1.13 (0.96–1.31) 0.88 (0.74–1.06) 0.682 0.97 (0.92–1.02) 0.267  
Brain (C70–72)          0.159 
 Men 1,772 28,321 1.00 1.10 (0.97–1.24) 1.06 (0.90–1.25) 1.08 (0.91–1.28) 0.271 1.01 (0.96–1.06) 0.646  
 Women 1,630 27,489 1.00 0.97 (0.85–1.10) 1.14 (0.93–1.40) 0.77 (0.60–1.00) 0.200 0.95 (0.89–1.02) 0.195  
 Combined 3,402 55,809 1.00 1.04 (0.95–1.13) 1.09 (0.96–1.24) 0.96 (0.83–1.11) 0.905 0.99 (0.95–1.03) 0.703  
NHL (C96)          0.165 
 Men 3,409 62,098 1.00 1.15 (1.05–1.26) 1.08 (0.96–1.22) 1.25 (1.11–1.41) <0.001 1.06 (1.02–1.09) 0.001  
 Women 3,191 60,588 1.00 1.02 (0.93–1.12) 0.97 (0.83–1.14) 1.03 (0.87–1.22) 0.794 1.02 (0.97–1.06) 0.491  
 Combined 6,600 122,686 1.00 1.09 (1.02–1.16) 1.03 (0.94–1.14) 1.16 (1.05–1.28) 0.001 1.04 (1.02–1.07) 0.002  
Multiple myeloma (C88, C90)          0.780 
 Men 1,791 33,417 1.00 0.91 (0.81–1.04) 0.91 (0.77–1.09) 1.00 (0.84–1.18) 0.581 1.01 (0.96–1.06) 0.799  
 Women 1,720 33,003 1.00 1.02 (0.90–1.16) 0.94 (0.76–1.17) 0.90 (0.71–1.14) 0.395 0.99 (0.93–1.06) 0.774  
 Combined 3,511 66,420 1.00 0.97 (0.89–1.06) 0.93 (0.81–1.06) 0.97 (0.84–1.11) 0.353 1.00 (0.96–1.04) 0.955  
Leukemia (C91–C95)          0.195 
 Men 3,551 66,047 1.00 1.03 (0.94–1.12) 0.99 (0.88–1.12) 0.98 (0.86–1.12) 0.829 0.99 (0.95–1.03) 0.554  
 Women 2,768 53,543 1.00 1.07 (0.97–1.18) 1.04 (0.88–1.23) 1.17 (0.98–1.38) 0.054 1.02 (0.98–1.07) 0.342  
 Combined 6,319 119,590 1.00 1.05 (0.98–1.12) 1.01 (0.91–1.11) 1.04 (0.94–1.15) 0.375 1.00 (0.97–1.03) 0.992  
SSB consumptionaContinuousb
Cancer site/typeDeathsPerson yearsNever (ref)<1 drink/day1 drink/day2+ drinks/dayPtrendPer 1 drink/dayP valuePinteraction
All cancers          <0.0001 
 Men 70,834 1,226,073 1.00 0.98 (0.96–1.00) 0.96 (0.94–0.99) 0.99 (0.96–1.02) 0.073 1.00 (0.99–1.00) 0.356  
 Women 64,259 1,188,795 1.00 0.98 (0.96–1.00) 1.01 (0.98–1.04) 1.01 (0.98–1.05) 0.807 1.00 (0.99–1.01) 0.352  
 Combined 135,093 2,414,868 1.00 0.98 (0.96–0.99) 0.98 (0.95–1.00) 0.99 (0.97–1.01) 0.061 1.00 (0.99–1.00) 0.462  
Obesity-related cancersc          0.311 
 Men 20,595 351,011 1.00 0.98 (0.95–1.02) 0.98 (0.94–1.03) 1.06 (1.01–1.12) 0.082 1.02 (1.00–1.03) 0.033  
 Women 30,018 542,434 1.00 1.00 (0.97–1.03) 1.02 (0.97–1.07) 1.03 (0.97–1.08) 0.268 1.01 (1.00–1.03) 0.101  
 Combined 50,613 893,445 1.00 0.99 (0.97–1.02) 1.00 (0.97–1.04) 1.05 (1.01–1.08) 0.057 1.01 (1.00–1.02) 0.009  
Larynx/oral cavity/pharynx (C01-C14, C32)          0.366 
 Men 1,215 19,894 1.00 0.78 (0.66–0.93) 1.04 (0.85–1.27) 0.99 (0.81–1.22) 0.781 1.00 (0.94–1.06) 0.964  
 Women 637 11,796 1.00 0.93 (0.75–1.17) 0.85 (0.59–1.22) 1.20 (0.87–1.65) 0.621 1.05 (0.96–1.15) 0.257  
 Combined 1,852 31,691 1.00 0.83 (0.73–0.95) 0.98 (0.82–1.17) 1.04 (0.87–1.24) 0.963 1.01 (0.97–1.06) 0.607  
Esophageal (C15)          0.317 
 Mend 2,080 37,313 1.00 0.96 (0.85–1.08) 0.81 (0.68–0.95) 0.90 (0.76–1.05) 0.038 0.97 (0.92–1.01) 0.158  
 Women 647 12,829 1.00 0.91 (0.74–1.13) 0.83 (0.57–1.20) 0.77 (0.51–1.15) 0.100 0.94 (0.84–1.05) 0.269  
 Combined 2,727 50,142 1.00 0.95 (0.86–1.05) 0.82 (0.70–0.95) 0.88 (0.76–1.03) 0.016 0.97 (0.92–1.01) 0.108  
Stomach (C16)          0.967 
 Men 1,716 25,184 1.00 0.86 (0.75–0.98) 1.20 (1.02–1.41) 1.14 (0.96–1.35) 0.074 1.04 (0.99–1.09) 0.126  
 Women 1,082 18,213 1.00 1.00 (0.85–1.18) 1.17 (0.91–1.51) 0.95 (0.71–1.27) 0.841 1.03 (0.96–1.11) 0.371  
 Combined 2,798 43,397 1.00 0.91 (0.82–1.01) 1.19 (1.04–1.37) 1.08 (0.94–1.25) 0.128 1.03 (0.99–1.08) 0.089  
Liver (C22)          0.763 
 Men 1,576 30,433 1.00 1.04 (0.91–1.19) 0.97 (0.81–1.17) 1.06 (0.89–1.27) 0.589 1.02 (0.97–1.08) 0.345  
 Women 1,146 23,971 1.00 0.99 (0.85–1.16) 0.86 (0.66–1.13) 1.13 (0.88–1.45) 0.700 1.02 (0.95–1.10) 0.520  
 Combined 2,722 54,404 1.00 1.02 (0.92–1.12) 0.93 (0.80–1.08) 1.07 (0.92–1.24) 0.648 1.02 (0.98–1.06) 0.340  
Pancreas (C25)          0.220 
 Men 4,339 76,644 1.00 1.00 (0.92–1.08) 0.98 (0.88–1.09) 1.09 (0.98–1.22) 0.223 1.01 (0.98–1.04) 0.499  
 Women 4,857 93,975 1.00 1.00 (0.92–1.08) 1.03 (0.91–1.17) 0.91 (0.79–1.05) 0.343 0.99 (0.95–1.03) 0.570  
 Combined 9,196 170,619 1.00 0.99 (0.94–1.05) 1.00 (0.92–1.08) 1.02 (0.94–1.11) 0.754 1.00 (0.98–1.03) 0.864  
Gall bladder (C23–24)          0.722 
 Men 378 6,430 1.00 1.38 (1.06–1.78) 1.44 (1.03–2.02) 1.05 (0.7–1.57) 0.218 1.04 (0.94–1.15) 0.499  
 Women 646 10,874 1.00 1.19 (0.98–1.46) 1.07 (0.76–1.52) 1.24 (0.88–1.74) 0.121 1.03 (0.94–1.14) 0.478  
 Combined 1,024 17,304 1.00 1.26 (1.07–1.47) 1.23 (0.97–1.56) 1.13 (0.87–1.47) 0.060 1.03 (0.96–1.11) 0.370  
Lung (C33–34)          0.005 
 Men 20,121 327,494 1.00 0.90 (0.87–0.94) 0.91 (0.86–0.96) 0.90 (0.85–0.94) <0.0001 0.97 (0.96–0.99) <0.0001  
 Women 14,260 265,675 1.00 0.89 (0.85–0.93) 0.97 (0.90–1.04) 0.95 (0.88–1.02) 0.011 0.99 (0.97–1.01) 0.163  
 Combined 34,381 593,169 1.00 0.90 (0.87–0.92) 0.93 (0.89–0.97) 0.91 (0.87–0.95) <0.0001 0.98 (0.96–0.99) <0.0001  
Small intestine (C17)          N/A 
 Combined 324 5,749 1.00 0.95 (0.71–1.28) 0.76 (0.47–1.23) 1.26 (0.84–1.90) 0.609 1.01 (0.89–1.14) 0.899  
Colorectal (C18–21)          0.384 
 Men 6,660 105,640 1.00 1.00 (0.94–1.07) 1.00 (0.91–1.09) 1.09 (1.00–1.19) 0.109 1.02 (0.99–1.04) 0.164  
 Women 7,092 123,386 1.00 0.97 (0.91–1.04) 1.15 (1.04–1.27) 1.09 (0.98–1.21) 0.035 1.03 (1.00–1.06) 0.046  
 Combined 13,752 229,025 1.00 0.99 (0.94–1.03) 1.06 (0.99–1.13) 1.09 (1.02–1.17) 0.011 1.02 (1.00–1.04) 0.021  
Breaste (C50)          N/A 
 Women, post-menopausal 6,074 104,596 1.00 0.98 (0.92–1.05) 1.01 (0.90–1.13) 1.05 (0.93–1.19) 0.558 1.00 (0.96–1.03) 0.835  
Uteruse,f (C54-C55)          N/A 
 Women 1,693 31,754 1.00 1.09 (0.96–1.23) 1.00 (0.80–1.23) 1.17 (0.95–1.45) 0.136 1.04 (0.98–1.11) 0.148  
Ovarye,f (C56)          N/A 
 Women 3,225 56,993 1.00 1.05 (0.95–1.14) 0.91 (0.77–1.06) 0.99 (0.84–1.17) 0.761 1.01 (0.97–1.06) 0.656  
Prostate (C61)          N/A 
 Men 9,381 171,583 1.00 1.01 (0.95–1.06) 0.91 (0.84–0.98) 1.01 (0.93–1.09) 0.570 0.99 (0.97–1.01) 0.299  
Kidney (C64-C66, C68)          0.385 
 Men 1,921 33,276 1.00 0.99 (0.87–1.11) 0.95 (0.81–1.12) 1.13 (0.96–1.32) 0.278 1.05 (1.01–1.10) 0.022  
 Womend 1,208 22,086 1.00 1.06 (0.91–1.23) 0.99 (0.76–1.27) 1.29 (1.02–1.64) 0.063 1.09 (1.02–1.16) 0.008  
 Combined 3,129 55,363 1.00 1.01 (0.92–1.11) 0.97 (0.84–1.11) 1.17 (1.03–1.34) 0.056 1.06 (1.02–1.10) 0.001  
Bladder (C67)          0.535 
 Men 2,431 48,116 1.00 1.06 (0.95–1.18) 1.12 (0.97–1.29) 1.13 (0.97–1.31) 0.041 1.04 (1.00–1.08) 0.071  
 Women 988 20,179 1.00 1.01 (0.85–1.19) 1.02 (0.76–1.35) 1.07 (0.79–1.43) 0.686 0.99 (0.91–1.08) 0.811  
 Combined 3,419 68,295 1.00 1.04 (0.95–1.14) 1.09 (0.96–1.24) 1.11 (0.97–1.27) 0.050 1.03 (0.99–1.07) 0.146  
Melanoma (C43)          0.209 
 Men 1,412 26,399 1.00 1.07 (0.94–1.23) 1.14 (0.96–1.37) 0.84 (0.68–1.04) 0.491 0.96 (0.90–1.02) 0.156  
 Women 718 13,946 1.00 1.06 (0.87–1.28) 1.07 (0.78–1.47) 1.02 (0.72–1.45) 0.695 1.01 (0.92–1.12) 0.793  
 Combined 2,130 40,346 1.00 1.07 (0.95–1.19) 1.13 (0.96–1.31) 0.88 (0.74–1.06) 0.682 0.97 (0.92–1.02) 0.267  
Brain (C70–72)          0.159 
 Men 1,772 28,321 1.00 1.10 (0.97–1.24) 1.06 (0.90–1.25) 1.08 (0.91–1.28) 0.271 1.01 (0.96–1.06) 0.646  
 Women 1,630 27,489 1.00 0.97 (0.85–1.10) 1.14 (0.93–1.40) 0.77 (0.60–1.00) 0.200 0.95 (0.89–1.02) 0.195  
 Combined 3,402 55,809 1.00 1.04 (0.95–1.13) 1.09 (0.96–1.24) 0.96 (0.83–1.11) 0.905 0.99 (0.95–1.03) 0.703  
NHL (C96)          0.165 
 Men 3,409 62,098 1.00 1.15 (1.05–1.26) 1.08 (0.96–1.22) 1.25 (1.11–1.41) <0.001 1.06 (1.02–1.09) 0.001  
 Women 3,191 60,588 1.00 1.02 (0.93–1.12) 0.97 (0.83–1.14) 1.03 (0.87–1.22) 0.794 1.02 (0.97–1.06) 0.491  
 Combined 6,600 122,686 1.00 1.09 (1.02–1.16) 1.03 (0.94–1.14) 1.16 (1.05–1.28) 0.001 1.04 (1.02–1.07) 0.002  
Multiple myeloma (C88, C90)          0.780 
 Men 1,791 33,417 1.00 0.91 (0.81–1.04) 0.91 (0.77–1.09) 1.00 (0.84–1.18) 0.581 1.01 (0.96–1.06) 0.799  
 Women 1,720 33,003 1.00 1.02 (0.90–1.16) 0.94 (0.76–1.17) 0.90 (0.71–1.14) 0.395 0.99 (0.93–1.06) 0.774  
 Combined 3,511 66,420 1.00 0.97 (0.89–1.06) 0.93 (0.81–1.06) 0.97 (0.84–1.11) 0.353 1.00 (0.96–1.04) 0.955  
Leukemia (C91–C95)          0.195 
 Men 3,551 66,047 1.00 1.03 (0.94–1.12) 0.99 (0.88–1.12) 0.98 (0.86–1.12) 0.829 0.99 (0.95–1.03) 0.554  
 Women 2,768 53,543 1.00 1.07 (0.97–1.18) 1.04 (0.88–1.23) 1.17 (0.98–1.38) 0.054 1.02 (0.98–1.07) 0.342  
 Combined 6,319 119,590 1.00 1.05 (0.98–1.12) 1.01 (0.91–1.11) 1.04 (0.94–1.15) 0.375 1.00 (0.97–1.03) 0.992  

aHRs and 95% CIs were obtained from Cox proportional hazards models. All analyses stratified by age at 1982 baseline (years). HRs were adjusted for race/ethnicity (White; Black; other (Asian, Hispanic or other)/unknown), smoking (never; former, 20 years since quit; former, 10–<20; former, <10 years; former, unknown years; current, <20 cigarettes per day; current, 20–<40; current, 40+; current, unknown; unknown smoking status), marital status (married; single; separated or divorced; widowed; unknown), education (some high school; high school grad; some college; college grad; graduate school; unknown), red and processed meat consumption (<=3 servings/wk; >3–5 servings/wk; >5–7 servings/wk; >1 servings/d; unknown), fruit and vegetable consumption (<= 1 servings/day; >1–2 servings/day; >2 servings/day; unknown), alcohol consumption (nondrinkers; <daily consumption; 1 drink/day; 2+ drinks/day; former drinkers), and ASB consumption (never; <1 drink/day; 1 drink/day; 2+ drinks/day). Ptrend for categorical intake used a continuous variable based on median intake across categories.

bPtrend for continuous models used sugar-sweetened beverages (drinks/d); Pinteraction by sex.

cIncludes deaths from cancers of the esophagus, stomach, colorectum, liver, gallbladder, pancreas, post-menopausal breast, uterus/endometrium, ovary and kidney, and multiple myeloma.

dSignificant interaction with time P < 0.05.

eFemale-only cancers (of the breast, uterus and ovary) additionally controlled for parity (nulliparous; 1 live birth; 2+ live births; missing/unknown), age at menarche (<12 years; 12 years; 13 years; >13 years; unknown/missing), estrogen use (never; current; former; unknown), oral contraceptive use (never; ever; unknown), age at first live birth (nulliparous; <20 years; 20–<25; 25–<30; 30+; missing/unknown age), and menopausal status (premenopausal; perimenopausal; postmenopausal; unknown).

fUterine and ovarian cancer mortality analyses excluded women who reported a history of hysterectomy, uterine surgery, or surgically induced menopause. Ovarian cancer mortality analyses also excluded women who reported a history of oophorectomy.

The Cox proportional hazards assumption, and interactions of SSBs and ASBs with sex and BMI, were tested by including a cross product term of continuous SSB or ASB (drinks/day) with continuous time, BMI, or sex in the final model, using the Wald Test. P values < 0.05 were considered statistically significant. Ptrend in categorical models was evaluated using median values in each beverage category and modeling as a continuous variable. All analyses were performed using Statistical Analysis Software (SAS) version 9.4 (SAS Institute Inc.).

Data availability

The data generated in this study can be requested according to CPS-II data access policies and procedures, available at www.cancer.org.

During a median of 27.7 (IQR, 17.4–34.3) years of follow-up, 135,093 CPS-II participants died from cancer (25.9% of all deaths). Baseline characteristics of study participants according to distribution of SSB and ASB intake are provided in Table 1. Compared with nonconsumers of SSBs, daily consumers tended to be younger, male, Black or other race/ethnicity, current smokers, to have higher BMI, to not drink alcohol, to have lower educational attainment, lower fruit and vegetable and coffee intake, and higher red and processed meat intake. In contrast, those who drank ASBs regularly were more often women, White, former smokers, and fruit, vegetable, and decaffeinated coffee consumers. ASB drinkers were more likely than SSB drinkers to have overweight or obese BMI.

SSB

Combined cancer endpoints

SSB consumption was not associated with all-cancer mortality in men, women, or in both sexes combined (Table 2). However, consumption of ≥2 servings of SSB/day, compared with never consumption, was associated with a 5% increased risk of BMI-related cancers in men and women combined (HR, 1.05; 95% CI, 1.01–1.08; Ptrend = 0.057), with 1% to 2% increased risk per drink/day in men (Ptrend = 0.033) and in both sexes combined (Ptrend = 0.009).

After including BMI in the model (Supplementary Table S1), the effect estimates for SSB consumption and BMI-related cancers combined was null.

Individual cancers

Of the individual cancers, SSB consumption was positively associated with risk of colorectal cancer (HR for ≥2/day vs. never = 1.09; 95% CI, 1.02–1.17; Ptrend = 0.011) and kidney cancer (HR, 1.17; 95% CI, 1.03–1.34; Ptrend = 0.056) in men and women combined, and non-Hodgkin lymphoma (NHL) in men (HR, 1.25; 95% CI, 1.11–1.41; Ptrend < 0.001), and men and women combined (HR, 1.16; 95% CI, 1.05–1.28; Ptrend = 0.001). Inverse associations of SSB consumption with lung cancer were observed. With inclusion of BMI in the model (Supplementary Table S1), the association with colorectal cancer, kidney cancer, NHL, and lung cancer remained or were slightly attenuated.

After restricting the analyses to never-smoking men and women to limit potential residual confounding from smoking history (Fig. 1; Supplementary Table S2), SSBs were no longer inversely associated with esophageal cancer (HR, 1.12; 95% CI, 0.83–1.51; Ptrend = 0.814) but remained statistically significantly inversely associated with lung cancer (HR, 0.81; 95% CI, 0.70–0.94; Ptrend < 0.001). Associations with colorectal cancer and kidney cancers were further from the null and higher, whereas the association with NHL was attenuated and not statistically significant. With further control for BMI (Supplementary Table S3), the association with colorectal cancer was only statistically significant for men.

Figure 1.

Associations of SSB consumption and cancer mortality among never smoking men and women in the CPS-II cohort. HRs and 95% CIs for ≥2 drinks/day versus never are adjusted for age, sex, race/ethnicity, marital status, education, smoking and for consumption of red and processed meat, fruits and vegetables, alcohol, and ASBs. Analyses of breast (postmenopausal), ovarian, and uterine cancer mortality additionally included parity, age at menarche, estrogen use, oral contraceptive use, and age at first live birth; ovarian and uterine cancer mortality analyses additionally included menopausal status.

Figure 1.

Associations of SSB consumption and cancer mortality among never smoking men and women in the CPS-II cohort. HRs and 95% CIs for ≥2 drinks/day versus never are adjusted for age, sex, race/ethnicity, marital status, education, smoking and for consumption of red and processed meat, fruits and vegetables, alcohol, and ASBs. Analyses of breast (postmenopausal), ovarian, and uterine cancer mortality additionally included parity, age at menarche, estrogen use, oral contraceptive use, and age at first live birth; ovarian and uterine cancer mortality analyses additionally included menopausal status.

Close modal

In models stratified by BMI (Supplementary Table S4), significant increased risk was limited to individuals with BMI ≥30 kg/m2 for all BMI-related cancers combined, cancers of the larynx/oral cavity/pharynx and kidney but the Pinteraction was not statistically significant.

ASBs

Combined cancer endpoints

ASB consumption (Table 3) was not associated with all-cancers combined, but a statistically significant increased risk of BMI-related cancers was observed. When BMI was included in the model, the association with obesity-related cancers was null and the association with all cancers combined was slightly inverse (Supplementary Table S5).

Table 3.

Associations (HR, 95% CI) of ASB consumption and all-cancer and site-specific cancer mortality in the CPS II cohort, 1982–2016.

ASB consumptionaContinuousb
Cancer site/typeDeathsPerson yearsNever (ref.)<1 drink/day1 drink/day2+ drinks/dayPtrendPer 1 drink/dP valuePinteraction
All cancers          0.335 
 Men 70,834 1,226,073 1.00 0.98 (0.95–1.00) 0.99 (0.95–1.02) 0.99 (0.96–1.03) 0.353 1.00 (0.99–1.01) 0.935  
 Women 64,259 1,188,795 1.00 0.97 (0.95–0.99) 0.98 (0.96–1.01) 0.98 (0.95–1.01) 0.054 0.99 (0.99–1.00) 0.101  
 Combined 135,093 2,414,868 1.00 0.98 (0.96–0.99) 0.99 (0.97–1.01) 0.99 (0.97–1.02) 0.227 1.00 (0.99–1.00) 0.691  
Obesity-related cancersc          0.259 
 Men 20,595 351,011 1.00 1.02 (0.97–1.07) 1.06 (1.00–1.13) 1.08 (1.02–1.15) 0.002 1.03 (1.01–1.04) 0.002  
 Women 30,018 542,434 1.00 1.02 (0.99–1.05) 1.04 (0.99–1.08) 1.03 (0.99–1.08) 0.038 1.01 (1.00–1.03) 0.031  
 Combined 50,613 893,445 1.00 1.02 (0.99–1.05) 1.04 (1.01–1.08) 1.05 (1.01–1.08) 0.001 1.02 (1.01–1.03) 0.001  
Larynx/oral cavity/pharynx (C01–C14, C32)          0.197 
 Men 1,215 19,894 1.00 1.18 (0.94–1.48) 1.34 (1.05–1.70) 1.09 (0.83–1.41) 0.093 1.06 (0.99–1.13) 0.079  
 Women 637 11,796 1.00 0.66 (0.50–0.87) 0.86 (0.64–1.17) 1.02 (0.78–1.35) 0.601 0.98 (0.90–1.06) 0.586  
 Combined 1,852 31,691 1.00 0.91 (0.77–1.09) 1.12 (0.93–1.35) 1.08 (0.90–1.31) 0.319 1.03 (0.98–1.08) 0.293  
Esophageal (C15)          0.475 
 Men 2,080 37,313 1.00 0.97 (0.82–1.15) 1.01 (0.83–1.22) 1.01 (0.83–1.23) 0.946 1.01 (0.96–1.06) 0.701  
 Women 647 12,829 1.00 1.11 (0.89–1.39) 0.78 (0.58–1.07) 0.91 (0.67–1.22) 0.326 0.99 (0.91–1.07) 0.830  
 Combined 2,727 50,142 1.00 1.01 (0.88–1.15) 0.93 (0.79–1.09) 0.97 (0.83–1.15) 0.554 1.00 (0.96–1.05) 0.879  
Stomach (C16)          0.203 
 Men 1,716 25,184 1.00 0.89 (0.73–1.08) 0.99 (0.79–1.23) 1.16 (0.94–1.43) 0.351 1.04 (0.98–1.10) 0.202  
 Women 1,082 18,213 1.00 0.97 (0.81–1.16) 0.90 (0.71–1.14) 1.04 (0.83–1.32) 0.957 0.98 (0.92–1.05) 0.643  
 Combined 2,798 43,397 1.00 0.94 (0.82–1.07) 0.94 (0.80–1.11) 1.10 (0.94–1.28) 0.580 1.01 (0.97–1.06) 0.572  
Liver (C22)          0.618 
 Men 1,576 30,433 1.00 1.18 (0.99–1.41) 1.16 (0.95–1.43) 1.12 (0.90–1.39) 0.083 1.02 (0.97–1.09) 0.434  
 Women 1,146 23,971 1.00 1.01 (0.85–1.19) 1.02 (0.83–1.25) 1.00 (0.80–1.24) 0.964 1.00 (0.94–1.07) 0.904  
 Combined 2,722 54,404 1.00 1.09 (0.96–1.23) 1.09 (0.94–1.26) 1.05 (0.90–1.22) 0.256 1.01 (0.97–1.05) 0.613  
Pancreas (C25)          0.419 
 Men 4,339 76,644 1.00 0.99 (0.88–1.11) 1.14 (1.01–1.29) 1.20 (1.06–1.37) 0.001 1.05 (1.02–1.09) 0.003  
 Women 4,857 93,975 1.00 1.05 (0.97–1.14) 1.06 (0.96–1.18) 1.13 (1.02–1.25) 0.010 1.03 (1.00–1.06) 0.030  
 Combined 9,196 170,619 1.00 1.03 (0.97–1.11) 1.09 (1.01–1.18) 1.16 (1.07–1.26) <0.0001 1.04 (1.02–1.06) <0.0001  
Gall bladder (C23–24)          N/A 
 Combined 1,024 17,304 1.00 1.19 (0.99–1.44) 1.26 (1.01–1.59) 1.25 (0.98–1.59) 0.011 1.07 (1.01–1.14) 0.027  
Lung (C33–34)          0.435 
 Men 20,121 327,494 1.00 0.91 (0.86–0.96) 0.88 (0.82–0.95) 0.90 (0.84–0.96) <0.0001 0.97 (0.95–0.99) 0.002  
 Women 14,260 265,675 1.00 0.87 (0.83–0.92) 0.86 (0.81–0.91) 0.82 (0.77–0.87) <0.0001 0.95 (0.93–0.96) <0.0001  
 Combined 34,381 593,169 1.00 0.89 (0.86–0.93) 0.88 (0.84–0.92) 0.87 (0.83–0.91) <0.0001 0.96 (0.95–0.97) <0.0001  
Small intestine (C17)          N/A 
 Combined 324 5,749 1.00 1.00 (0.69–1.45) 1.13 (0.74–1.71) 1.33 (0.89–2.00) 0.162 1.12 (1.01–1.23) 0.033  
Colorectal (C18–21)          0.448 
 Men 6,660 105,640 1.00 1.05 (0.96–1.15) 1.00 (0.90–1.12) 1.01 (0.91–1.13) 0.680 1.01 (0.98–1.04) 0.467  
 Women 7,092 123,386 1.00 0.97 (0.90–1.04) 1.05 (0.97–1.14) 0.94 (0.86–1.03) 0.431 1.00 (0.97–1.02) 0.780  
 Combined 13,752 229,025 1.00 0.99 (0.94–1.05) 1.03 (0.97–1.11) 0.97 (0.90–1.04) 0.704 1.00 (0.98–1.02) 0.802  
Breastd (C50)          N/A 
 Women, post- menopausal 6,074 104,596 1.00 1.02 (0.94–1.10) 0.97 (0.88–1.06) 1.10 (1.00–1.20) 0.153 1.03 (1.00–1.06) 0.032  
Uterusd,e (C54-C55)          N/A 
 Women 1,693 31,754 1.00 1.04 (0.90–1.19) 1.07 (0.90–1.26) 1.18 (1.00–1.40) 0.049 1.04 (0.99–1.09) 0.130  
Ovaryd,e (C56)          N/A 
 Women 3,225 56,993 1.00 1.07 (0.97–1.18) 1.17 (1.05–1.32) 1.03 (0.91–1.17) 0.137 1.01 (0.98–1.05) 0.554  
Prostate (C61)          N/A 
 Men 9,381 171,583 1.00 0.99 (0.92–1.07) 0.91 (0.83–1.00) 0.98 (0.89–1.08) 0.258 0.99 (0.96–1.02) 0.424  
Kidney (C64-C66, C68)          0.404 
 Men 1,921 33,276 1.00 0.96 (0.80–1.14) 1.09 (0.90–1.33) 1.07 (0.88–1.31) 0.377 1.03 (0.97–1.08) 0.317  
 Women 1,208 22,086 1.00 1.00 (0.84–1.18) 1.07 (0.87–1.30) 1.01 (0.81–1.25) 0.776 0.99 (0.94–1.06) 0.842  
 Combined 3,129 55,363 1.00 0.98 (0.87–1.11) 1.08 (0.94–1.24) 1.04 (0.90–1.20) 0.412 1.01 (0.97–1.05) 0.555  
Bladder (C67)          0.506 
 Men 2,431 48,116 1.00 0.94 (0.80–1.10) 0.97 (0.81–1.17) 1.09 (0.91–1.31) 0.574 1.00 (0.95–1.05) 0.947  
 Women 988 20,179 1.00 0.96 (0.79–1.16) 1.02 (0.81–1.29) 0.96 (0.75–1.23) 0.784 0.98 (0.92–1.06) 0.645  
 Combined 3,419 68,295 1.00 0.94 (0.83–1.06) 0.99 (0.86–1.14) 1.04 (0.90–1.20) 0.794 1.00 (0.95–1.04) 0.817  
Melanoma (C43)          0.619 
 Menf 1,412 26,399 1.00 0.93 (0.77–1.14) 1.09 (0.89–1.35) 1.03 (0.82–1.29) 0.679 1.02 (0.96–1.09) 0.434  
 Women 718 13,946 1.00 0.95 (0.77–1.18) 0.97 (0.75–1.25) 1.04 (0.80–1.36) 0.908 1.00 (0.92–1.08) 0.936  
 Combined 2,130 40,346 1.00 0.94 (0.82–1.09) 1.04 (0.88–1.22) 1.04 (0.88–1.24) 0.643 1.02 (0.97–1.06) 0.540  
Brain (C70–72)          0.740 
 Men 1,772 28,321 1.00 1.02 (0.86–1.21) 1.06 (0.87–1.29) 0.95 (0.77–1.18) 0.910 0.99 (0.93–1.05) 0.677  
 Women 1,630 27,489 1.00 1.10 (0.96–1.26) 0.94 (0.79–1.12) 0.98 (0.82–1.17) 0.764 0.98 (0.93–1.04) 0.521  
 Combined 3,402 55,809 1.00 1.06 (0.96–1.18) 0.99 (0.87–1.12) 0.96 (0.84–1.11) 0.714 0.98 (0.95–1.02) 0.418  
NHL (C96)          0.756 
 Menf 3,409 62,098 1.00 1.04 (0.92–1.18) 1.02 (0.88–1.18) 1.01 (0.87–1.18) 0.704 1.01 (0.97–1.05) 0.676  
 Women 3,191 60,588 1.00 0.97 (0.87–1.07) 0.98 (0.87–1.12) 1.08 (0.95–1.23) 0.383 1.02 (0.98–1.06) 0.274  
 Combinedf 6,600 122,686 1.00 1.00 (0.92–1.08) 1.00 (0.91–1.10) 1.05 (0.95–1.16) 0.382 1.01 (0.99–1.04) 0.300  
Multiple myeloma (C88–C90)          0.903 
 Men 1,791 33,417 1.00 1.04 (0.88–1.24) 1.00 (0.82–1.22) 1.07 (0.87–1.31) 0.536 1.02 (0.97–1.08) 0.392  
 Women 1,720 33,003 1.00 1.00 (0.87–1.15) 1.05 (0.89–1.24) 1.05 (0.88–1.25) 0.499 1.03 (0.98–1.08) 0.259  
 Combined 3,511 66,420 1.00 1.02 (0.92–1.13) 1.03 (0.91–1.17) 1.06 (0.93–1.21) 0.357 1.03 (0.99–1.07) 0.147  
Leukemia (C91–C95)          0.809 
 Men 3,551 66,047 1.00 0.97 (0.86–1.10) 1.10 (0.95–1.26) 1.01 (0.87–1.18) 0.569 1.01 (0.97–1.05) 0.707  
 Women 2,768 53,543 1.00 1.00 (0.89–1.11) 0.98 (0.86–1.12) 1.02 (0.88–1.17) 0.935 1.00 (0.96–1.04) 0.979  
 Combined 6,319 119,590 1.00 0.99 (0.91–1.07) 1.03 (0.94–1.14) 1.01 (0.91–1.12) 0.705 1.00 (0.97–1.03) 0.859  
ASB consumptionaContinuousb
Cancer site/typeDeathsPerson yearsNever (ref.)<1 drink/day1 drink/day2+ drinks/dayPtrendPer 1 drink/dP valuePinteraction
All cancers          0.335 
 Men 70,834 1,226,073 1.00 0.98 (0.95–1.00) 0.99 (0.95–1.02) 0.99 (0.96–1.03) 0.353 1.00 (0.99–1.01) 0.935  
 Women 64,259 1,188,795 1.00 0.97 (0.95–0.99) 0.98 (0.96–1.01) 0.98 (0.95–1.01) 0.054 0.99 (0.99–1.00) 0.101  
 Combined 135,093 2,414,868 1.00 0.98 (0.96–0.99) 0.99 (0.97–1.01) 0.99 (0.97–1.02) 0.227 1.00 (0.99–1.00) 0.691  
Obesity-related cancersc          0.259 
 Men 20,595 351,011 1.00 1.02 (0.97–1.07) 1.06 (1.00–1.13) 1.08 (1.02–1.15) 0.002 1.03 (1.01–1.04) 0.002  
 Women 30,018 542,434 1.00 1.02 (0.99–1.05) 1.04 (0.99–1.08) 1.03 (0.99–1.08) 0.038 1.01 (1.00–1.03) 0.031  
 Combined 50,613 893,445 1.00 1.02 (0.99–1.05) 1.04 (1.01–1.08) 1.05 (1.01–1.08) 0.001 1.02 (1.01–1.03) 0.001  
Larynx/oral cavity/pharynx (C01–C14, C32)          0.197 
 Men 1,215 19,894 1.00 1.18 (0.94–1.48) 1.34 (1.05–1.70) 1.09 (0.83–1.41) 0.093 1.06 (0.99–1.13) 0.079  
 Women 637 11,796 1.00 0.66 (0.50–0.87) 0.86 (0.64–1.17) 1.02 (0.78–1.35) 0.601 0.98 (0.90–1.06) 0.586  
 Combined 1,852 31,691 1.00 0.91 (0.77–1.09) 1.12 (0.93–1.35) 1.08 (0.90–1.31) 0.319 1.03 (0.98–1.08) 0.293  
Esophageal (C15)          0.475 
 Men 2,080 37,313 1.00 0.97 (0.82–1.15) 1.01 (0.83–1.22) 1.01 (0.83–1.23) 0.946 1.01 (0.96–1.06) 0.701  
 Women 647 12,829 1.00 1.11 (0.89–1.39) 0.78 (0.58–1.07) 0.91 (0.67–1.22) 0.326 0.99 (0.91–1.07) 0.830  
 Combined 2,727 50,142 1.00 1.01 (0.88–1.15) 0.93 (0.79–1.09) 0.97 (0.83–1.15) 0.554 1.00 (0.96–1.05) 0.879  
Stomach (C16)          0.203 
 Men 1,716 25,184 1.00 0.89 (0.73–1.08) 0.99 (0.79–1.23) 1.16 (0.94–1.43) 0.351 1.04 (0.98–1.10) 0.202  
 Women 1,082 18,213 1.00 0.97 (0.81–1.16) 0.90 (0.71–1.14) 1.04 (0.83–1.32) 0.957 0.98 (0.92–1.05) 0.643  
 Combined 2,798 43,397 1.00 0.94 (0.82–1.07) 0.94 (0.80–1.11) 1.10 (0.94–1.28) 0.580 1.01 (0.97–1.06) 0.572  
Liver (C22)          0.618 
 Men 1,576 30,433 1.00 1.18 (0.99–1.41) 1.16 (0.95–1.43) 1.12 (0.90–1.39) 0.083 1.02 (0.97–1.09) 0.434  
 Women 1,146 23,971 1.00 1.01 (0.85–1.19) 1.02 (0.83–1.25) 1.00 (0.80–1.24) 0.964 1.00 (0.94–1.07) 0.904  
 Combined 2,722 54,404 1.00 1.09 (0.96–1.23) 1.09 (0.94–1.26) 1.05 (0.90–1.22) 0.256 1.01 (0.97–1.05) 0.613  
Pancreas (C25)          0.419 
 Men 4,339 76,644 1.00 0.99 (0.88–1.11) 1.14 (1.01–1.29) 1.20 (1.06–1.37) 0.001 1.05 (1.02–1.09) 0.003  
 Women 4,857 93,975 1.00 1.05 (0.97–1.14) 1.06 (0.96–1.18) 1.13 (1.02–1.25) 0.010 1.03 (1.00–1.06) 0.030  
 Combined 9,196 170,619 1.00 1.03 (0.97–1.11) 1.09 (1.01–1.18) 1.16 (1.07–1.26) <0.0001 1.04 (1.02–1.06) <0.0001  
Gall bladder (C23–24)          N/A 
 Combined 1,024 17,304 1.00 1.19 (0.99–1.44) 1.26 (1.01–1.59) 1.25 (0.98–1.59) 0.011 1.07 (1.01–1.14) 0.027  
Lung (C33–34)          0.435 
 Men 20,121 327,494 1.00 0.91 (0.86–0.96) 0.88 (0.82–0.95) 0.90 (0.84–0.96) <0.0001 0.97 (0.95–0.99) 0.002  
 Women 14,260 265,675 1.00 0.87 (0.83–0.92) 0.86 (0.81–0.91) 0.82 (0.77–0.87) <0.0001 0.95 (0.93–0.96) <0.0001  
 Combined 34,381 593,169 1.00 0.89 (0.86–0.93) 0.88 (0.84–0.92) 0.87 (0.83–0.91) <0.0001 0.96 (0.95–0.97) <0.0001  
Small intestine (C17)          N/A 
 Combined 324 5,749 1.00 1.00 (0.69–1.45) 1.13 (0.74–1.71) 1.33 (0.89–2.00) 0.162 1.12 (1.01–1.23) 0.033  
Colorectal (C18–21)          0.448 
 Men 6,660 105,640 1.00 1.05 (0.96–1.15) 1.00 (0.90–1.12) 1.01 (0.91–1.13) 0.680 1.01 (0.98–1.04) 0.467  
 Women 7,092 123,386 1.00 0.97 (0.90–1.04) 1.05 (0.97–1.14) 0.94 (0.86–1.03) 0.431 1.00 (0.97–1.02) 0.780  
 Combined 13,752 229,025 1.00 0.99 (0.94–1.05) 1.03 (0.97–1.11) 0.97 (0.90–1.04) 0.704 1.00 (0.98–1.02) 0.802  
Breastd (C50)          N/A 
 Women, post- menopausal 6,074 104,596 1.00 1.02 (0.94–1.10) 0.97 (0.88–1.06) 1.10 (1.00–1.20) 0.153 1.03 (1.00–1.06) 0.032  
Uterusd,e (C54-C55)          N/A 
 Women 1,693 31,754 1.00 1.04 (0.90–1.19) 1.07 (0.90–1.26) 1.18 (1.00–1.40) 0.049 1.04 (0.99–1.09) 0.130  
Ovaryd,e (C56)          N/A 
 Women 3,225 56,993 1.00 1.07 (0.97–1.18) 1.17 (1.05–1.32) 1.03 (0.91–1.17) 0.137 1.01 (0.98–1.05) 0.554  
Prostate (C61)          N/A 
 Men 9,381 171,583 1.00 0.99 (0.92–1.07) 0.91 (0.83–1.00) 0.98 (0.89–1.08) 0.258 0.99 (0.96–1.02) 0.424  
Kidney (C64-C66, C68)          0.404 
 Men 1,921 33,276 1.00 0.96 (0.80–1.14) 1.09 (0.90–1.33) 1.07 (0.88–1.31) 0.377 1.03 (0.97–1.08) 0.317  
 Women 1,208 22,086 1.00 1.00 (0.84–1.18) 1.07 (0.87–1.30) 1.01 (0.81–1.25) 0.776 0.99 (0.94–1.06) 0.842  
 Combined 3,129 55,363 1.00 0.98 (0.87–1.11) 1.08 (0.94–1.24) 1.04 (0.90–1.20) 0.412 1.01 (0.97–1.05) 0.555  
Bladder (C67)          0.506 
 Men 2,431 48,116 1.00 0.94 (0.80–1.10) 0.97 (0.81–1.17) 1.09 (0.91–1.31) 0.574 1.00 (0.95–1.05) 0.947  
 Women 988 20,179 1.00 0.96 (0.79–1.16) 1.02 (0.81–1.29) 0.96 (0.75–1.23) 0.784 0.98 (0.92–1.06) 0.645  
 Combined 3,419 68,295 1.00 0.94 (0.83–1.06) 0.99 (0.86–1.14) 1.04 (0.90–1.20) 0.794 1.00 (0.95–1.04) 0.817  
Melanoma (C43)          0.619 
 Menf 1,412 26,399 1.00 0.93 (0.77–1.14) 1.09 (0.89–1.35) 1.03 (0.82–1.29) 0.679 1.02 (0.96–1.09) 0.434  
 Women 718 13,946 1.00 0.95 (0.77–1.18) 0.97 (0.75–1.25) 1.04 (0.80–1.36) 0.908 1.00 (0.92–1.08) 0.936  
 Combined 2,130 40,346 1.00 0.94 (0.82–1.09) 1.04 (0.88–1.22) 1.04 (0.88–1.24) 0.643 1.02 (0.97–1.06) 0.540  
Brain (C70–72)          0.740 
 Men 1,772 28,321 1.00 1.02 (0.86–1.21) 1.06 (0.87–1.29) 0.95 (0.77–1.18) 0.910 0.99 (0.93–1.05) 0.677  
 Women 1,630 27,489 1.00 1.10 (0.96–1.26) 0.94 (0.79–1.12) 0.98 (0.82–1.17) 0.764 0.98 (0.93–1.04) 0.521  
 Combined 3,402 55,809 1.00 1.06 (0.96–1.18) 0.99 (0.87–1.12) 0.96 (0.84–1.11) 0.714 0.98 (0.95–1.02) 0.418  
NHL (C96)          0.756 
 Menf 3,409 62,098 1.00 1.04 (0.92–1.18) 1.02 (0.88–1.18) 1.01 (0.87–1.18) 0.704 1.01 (0.97–1.05) 0.676  
 Women 3,191 60,588 1.00 0.97 (0.87–1.07) 0.98 (0.87–1.12) 1.08 (0.95–1.23) 0.383 1.02 (0.98–1.06) 0.274  
 Combinedf 6,600 122,686 1.00 1.00 (0.92–1.08) 1.00 (0.91–1.10) 1.05 (0.95–1.16) 0.382 1.01 (0.99–1.04) 0.300  
Multiple myeloma (C88–C90)          0.903 
 Men 1,791 33,417 1.00 1.04 (0.88–1.24) 1.00 (0.82–1.22) 1.07 (0.87–1.31) 0.536 1.02 (0.97–1.08) 0.392  
 Women 1,720 33,003 1.00 1.00 (0.87–1.15) 1.05 (0.89–1.24) 1.05 (0.88–1.25) 0.499 1.03 (0.98–1.08) 0.259  
 Combined 3,511 66,420 1.00 1.02 (0.92–1.13) 1.03 (0.91–1.17) 1.06 (0.93–1.21) 0.357 1.03 (0.99–1.07) 0.147  
Leukemia (C91–C95)          0.809 
 Men 3,551 66,047 1.00 0.97 (0.86–1.10) 1.10 (0.95–1.26) 1.01 (0.87–1.18) 0.569 1.01 (0.97–1.05) 0.707  
 Women 2,768 53,543 1.00 1.00 (0.89–1.11) 0.98 (0.86–1.12) 1.02 (0.88–1.17) 0.935 1.00 (0.96–1.04) 0.979  
 Combined 6,319 119,590 1.00 0.99 (0.91–1.07) 1.03 (0.94–1.14) 1.01 (0.91–1.12) 0.705 1.00 (0.97–1.03) 0.859  

aHRs and 95% CIs were obtained from Cox proportional hazards models. All analyses stratified by age at 1982 baseline (years). HRs adjusted for race/ethnicity (white; black; other/unknown), smoking at 1982 baseline (never; former, 20 years since quit; former, 10–<20; former, <10 years; former, unknown years; current, <20 cigarettes per day; current, 20–<40; current, 40+; current, unknown; unknown smoking status), marital status (married; single; separated or divorced; widowed; unknown), education (some high school; high school grad; some college; college grad; graduate school; unknown), red and processed meat consumption (<=3 servings/week; >3–5 servings/week; >5–7 servings/week; >1 servings/day; unknown), fruit and vegetable consumption (<= 1 servings/day; >1–2 servings/day; >2 servings/d; unknown), alcohol consumption (nondrinkers; <daily consumption; 1 drink/day; 2+ drinks/day; former drinkers), and sugar-sweetened beverage consumption (never; <1 drink/day; 1 drink/day; 2+ drinks/day). Ptrend for categorical intake used a continuous variable based on median intake across categories.

bPtrend for continuous models used ASBs (drinks/day); Pinteraction by sex.

cIncludes deaths from cancers of the esophagus, stomach, colorectum, liver, gallbladder, pancreas, post-menopausal breast, uterus/endometrium, ovary and kidney, and multiple myeloma.

dFemale-only cancers (of the breast, uterus and ovary) additionally controlled for parity (nulliparous; 1 live birth; 2+ live births; missing/unknown), age at menarche (<12 years; 12 years; 13 years; >13 years; unknown/missing), estrogen use (never; current; former; unknown), oral contraceptive use (never; ever; unknown), age at first live birth (nulliparous; <20 years; 20–<25; 25–<30; 30+; missing/unknown age), and menopausal status (premenopausal; perimenopausal; postmenopausal; unknown).

eUterine and ovarian cancer mortality analyses excluded women who reported a history of hysterectomy, uterine surgery, or surgically induced menopause. Ovarian cancer mortality analyses also excluded women who reported a history of oophorectomy.

fSignificant interaction with time P < 0.05.

Individual cancers

In models not including BMI, ASB consumption was associated with a statistically significant 16% increased risk of pancreatic cancer (4% increase for each serving/day) in men and women combined and separately. High vs. low consumption of ASBs was also associated with increased risk of uterine and gall bladder cancers, and continuous models suggested increased risk of small intestinal and postmenopausal breast cancers (Table 3). After controlling for BMI, however, all associations became null, except for pancreatic cancer in men and both sexes combined (Supplementary Table S5). Regardless of BMI-adjustment, ASB consumption was statistically significantly associated with lower risk of death from lung cancer. However, among never-smokers (Fig. 2; Supplementary Table S6), this association became null, and a positive association emerged for liver cancer and melanoma (men only). With further control for BMI among never smokers (Supplementary Table S7), the association with liver cancer became null, but the positive association with pancreatic cancer persisted.

Figure 2.

Associations of ASB consumption and cancer mortality among never smoking men and women in the CPS-II cohort. HRs and 95% CIs for ≥2 drinks/day versus never are adjusted for age, sex, race/ethnicity, marital status, education, smoking and for consumption of red and processed meat, fruits and vegetables, alcohol, and SSBs. Analyses of breast (postmenopausal), ovarian, and uterine cancer mortality additionally included parity, age at menarche, estrogen use, oral contraceptive use, and age at first live birth; ovarian and uterine cancer mortality analyses additionally included menopausal status.

Figure 2.

Associations of ASB consumption and cancer mortality among never smoking men and women in the CPS-II cohort. HRs and 95% CIs for ≥2 drinks/day versus never are adjusted for age, sex, race/ethnicity, marital status, education, smoking and for consumption of red and processed meat, fruits and vegetables, alcohol, and SSBs. Analyses of breast (postmenopausal), ovarian, and uterine cancer mortality additionally included parity, age at menarche, estrogen use, oral contraceptive use, and age at first live birth; ovarian and uterine cancer mortality analyses additionally included menopausal status.

Close modal

In BMI-stratified models, a statistical interaction with ASB consumption was observed for prostate cancer and NHL, but all confidence intervals crossed 1.0 (Pinteraction < 0.03; Supplementary Table S8).

Sensitivity analyses

In sensitivity analyses, excluding the first 2 years of follow-up had minimal impact on the HRs. Cox proportional hazards violations were noted for a limited number of primarily smoking-related cancers, as indicated in the footnotes to Tables 2 and 3. Analyses stratified by 10-year follow-up time period for SSBs and ASBs, for men and women combined, are provided in Supplementary Figs. S1 and S2. Associations of SSBs with lung and esophageal cancers were most strongly inverse during the first 10-year follow-up period.

Among almost one million U.S. adults followed for up to 34 years, regular consumption of SSBs was not associated with death from all cancers combined but was associated with an increased risk of mortality from obesity-related cancers. Controlling for BMI eliminated the association, suggesting that SSBs may lead to increased mortality risk through excess body mass. Individual cancer mortality associated with SSB consumption included colorectal cancer, kidney and bladder cancers, and NHL; after controlling for BMI, associations with colorectal cancer, kidney cancer, and NHL persisted, suggesting BMI-independent mechanisms. Similarly, ASB consumption was positively associated with mortality risk from BMI-related cancers but was no longer associated when controlling for BMI. Because the link between ASB consumption and body weight is inconclusive, this suggests confounding by BMI. However, a positive association of ASB consumption with pancreatic cancer mortality was robust to adjustment for BMI and in analyses limited to never smokers. While confounding cannot be ruled out, this association deserves further study.

SSBs

Combined cancer endpoints

Excess body fatness is causally related to at least 13 cancer types (10), and the evidence of an association of SSBs with weight gain, overweight, and obesity is considered strong (8). The 5% increased risk of mortality from obesity-related cancers we observed with ≥2 SSBs/d vs. never, unadjusted for BMI, is consistent with findings of the Melbourne Collaborative Cohort which reported a 10% increased risk of BMI-related cancers for >1 drink/day vs. never or <1/month (33). High vs. low intake quintile of sugary beverages was associated with adiposity-related cancer risk in the Framingham cohort, but only among participants with excessive central adiposity, with an HR, 1.59; 95% CI, 1.01–2.50 (Ptrend = 0.057; ref. 34). Together, these studies provide support that increased risk of BMI-related cancer incidence and mortality with SSB consumption is due at least in part to BMI being in the causal pathway. Our study did not replicate BMI-independent positive associations of SSBs with risk of overall cancer mortality (28) or incidence (29), observed in two prior cohort studies, but is consistent with null findings for SSB intake and cancer mortality from the EPIC cohort (HR, 0.92; 95% CI, 0.78–1.09 for ≥2 glasses/day vs. <1 glass/month; ref. 30).

Individual cancers

Death from several individual cancers was also positively associated with SSB consumption in this study, particularly for colorectal cancer and kidney cancer. The risk of death from colorectal cancer was 9% higher with consumption of ≥2 drinks/day in CPS-II participants, an association that remained after controlling for BMI, and strengthened among never smokers. Although many previous studies reported positive associations between SSB and colorectal cancer risk or mortality (29, 30, 33, 34, 40, 41), most were not statistically significant. Hodge and colleagues (33) reported a 28% (95% CI, 4%–57%; Ptrend = 0.12) increased risk of colorectal cancer for ≥1/day versus <1/month of sugar-sweetened soft drinks, not controlling for BMI, in a study of Australian adults. A 2010 pooled analysis of 13 cohort studies including 5,604 incident cases and that adjusted for BMI (40) found no association (HR, 0.94; 95% CI, 0.66–1.32) with colon cancer risk comparing ≥550 g/day (about 18 oz) SSB to nonconsumption. A 2021 meta-analysis of four recent cohort studies reported nonstatistically significantly increased colorectal cancer risk for high versus low intake (HR, 1.18; 95% CI, 0.99–1.41; ref. 37); most studies included BMI in the model. Hur and colleagues (42) recently reported statistically significant two-fold (RR, 2.18) and three-fold (RR, 3.41) increased risks of early onset colorectal cancer with greater SSB consumption in adulthood and adolescence, respectively, with BMI adjustment. Our findings strengthen the available evidence of an association between SSBs and colorectal cancer mortality. SSB consumption may promote visceral adiposity (13, 14), independent of body weight, which then may alter adipokine secretion and cell-signaling pathways. In addition, among patients with stage III colon cancer who participated in an adjuvant chemoprevention trial, Meyerhardt and colleagues (43) found a higher risk of recurrence and mortality associated with higher glycemic load (calculated from quality and quantity of carbohydrates), which may contribute to hyperinsulinemia, cell proliferation, and inhibit apoptosis of micrometastases (43). High glycemic foods like SSBs may also contribute to diabetes risk and inflammation (11, 12, 44), both associated with colorectal cancer risk and mortality (45, 46).

Few studies have investigated the relationships between SSBs and kidney cancer risk or mortality (33, 47–49). In a recent analysis from the EPIC cohort, Heath and colleagues (48) reported no association of SSBs with kidney cancer mortality, including 356 deaths (HR, 0.97 per 100 mL/day). In the UK Million Women Study including 588 incident cases (49), a nonsignificant positive association was observed for intake of carbonated drinks (HR, 1.18; 95% CI, 0.89–1.58), although the study was unable to distinguish sweetener type. Likewise, a 2007 pooled analysis of 13 cohorts with 1,478 cases found no association of soda with renal cell cancer risk (HR, 1.11; 95% CI, 0.89–1.38), but that study was also unable to separate sugar- and artificially-sweetened soda (47). The Melbourne Collaborative Cohort Study, the only study to omit BMI from the model, observed a nonsignificant increased risk (HR, 1.48; 95% CI, 0.87–2.53) for ≥1/day vs. <1/month, with 146 cases. This study, with 3,429 cases, is the largest and first to report a statistically significant increased risk of kidney cancer mortality associated with SSB consumption. Because the HR was not strongly affected by controlling for BMI, and strengthened among never smokers, this relationship may involve a more direct mechanism as opposed to one solely mediated by BMI, including potentially carcinogenic chemical compounds from food coloring or packaging (11, 12, 29, 50–52). Further, SSB consumption may influence cancer risk or progression through metabolic perturbations and cell-cycle disruption (8, 12, 15). Finally, positive associations of SSB consumption with NHL mortality risk, while fairly robust to BMI adjustment, became null among never smokers, suggesting that these associations were susceptible to residual confounding by tobacco.

Counter to expectations, we observed inverse associations of SSB consumption with risk of esophageal and lung cancer mortality, which may be explained by reverse causality and/or residual confounding. Individuals experiencing symptoms of esophageal cancer may avoid carbonated beverages, especially close to the time of diagnosis. Inverse associations of SSB consumption and esophageal cancer were more pronounced within the first 10 years of follow-up compared with later periods, strengthening support for this potential source of bias. In addition, the association with esophageal cancer was null among never smokers, suggesting potential residual confounding by smoking. Stronger inverse associations with lung cancer mortality were also observed during the first 10 years of follow-up. Sugar sweetened beverage consumers were generally heavier, and smokers tend to be leaner. Among those with a BMI ≥30 kg/m2, the relationship of SSBs with lung cancer mortality was null, adding support to these explanations.

ASBs

Combined cancer endpoints

ASBs contribute the largest share of low-calorie sweeteners consumed worldwide (53). In contrast to the relationship of SSBs with weight gain and obesity (8), the evidence that ASB consumption leads to excess energy intake and obesity is inconclusive and weak (16, 17). In this study, ASB consumers were heavier, and ASB consumption was positively associated with risk of BMI-related cancer mortality. However, this association was null with control for BMI, suggesting potential confounding by BMI.

Individual cancers

Regarding individual cancers, mortality from breast cancer and endometrial cancer was increased only in models that excluded BMI. In contrast, we observed a significant positive association of ASB consumption with pancreatic cancer risk which persisted with control for BMI and in models of never smokers. Several explanations may exist for this finding. Diabetes is a pronounced risk factor for pancreatic cancer (54, 55), and individuals with diabetes would be more likely to consume ASBs. We excluded individuals with a history of diabetes at baseline to limit confounding by indication, but it is possible that undiagnosed diabetes influenced these results and that many ASB drinkers were diagnosed with diabetes after baseline. Residual confounding by BMI may also play a role, as ASB drinkers were heavier than nondrinkers in this study, and may have experienced longer-term excess body fatness. Higher BMI in early adulthood has been strongly associated with pancreatic cancer risk (56), and we were unable to control for early adulthood BMI. Support for a direct influence of artificial sweeteners on metabolism and potentially cancer-related pathways was found in a study of mice which reported that saccharin, sucralose, and aspartame altered intestinal microbiota in a manner that would lead to glucose intolerance (21); however, subsequent human studies have not been confirmatory (25). Three previous cohort studies (57–59) do not report associations of ASB consumption with pancreatic cancer risk or mortality, although data from the AARP cohort suggest increased risk (fourth quintile vs. first HR, 1.35; 95% CI, 1.03–1.77; fifth vs. first quintile HR, 1.25; 95% CI, 0.94–1.66; Ptrend = 0.19; ref. 59).

Strengths and limitations of this study are worth noting. The large cohort of both men and women prospectively followed for a maximum of 34 years including over 135,000 deaths from cancer enabled a comprehensive investigation of the association of these beverages with risk of 20 cancer types, including analyses stratified by sex and BMI, and limited to never smokers. However, as this was an observational study, causality cannot be inferred. We also acknowledge that measurement error was likely present due to only one measurement of diet at baseline, particularly as artificial sweeteners used in the food supply change over time (53, 60). Missing covariate data may have contributed to loss of power to detect associations, and confounded associations. By examining mortality associations, this study examined whether these beverages were associated with incidence and/or with survival from cancer, which are impossible to disentangle from mortality outcomes alone. Finally, we were unable to distinguish adenocarcinoma from squamous cell esophageal cancers, or cancers of the gastric cardia from other gastric cancers, which limited our ability to distinguish a BMI-mediated association for these cancers.

In summary, we observed positive associations of SSB consumption and BMI-related cancers overall, partly mediated by BMI, and BMI-independent associations with colorectal cancer and kidney cancer among both men and women. We also observed a robust, BMI-independent positive association of ASBs with pancreatic cancer mortality. Although SSB consumption has decreased in the United States, intake remains high, and ASB consumption levels are increasing. Continued research on the impact of both beverage types with cancer risk and mortality is warranted to determine whether these associations are causal or confounded by other lifestyle factors, and whether they are mediated through BMI.

M.A. Guinter reports personal fees from Flatiron Health, Inc. and Roche outside the submitted work. No disclosures were reported by the other authors.

M.L. McCullough: Conceptualization, supervision, methodology, writing–original draft. R.A. Hodge: Formal analysis, visualization, writing–review and editing. P.T. Campbell: Conceptualization, methodology, writing–review and editing. M.A. Guinter: Conceptualization, writing–review and editing. A.V. Patel: Methodology, writing–review and editing.

The authors express sincere appreciation to all Cancer Prevention Study II participants, and to each member of the study and biospecimen management group. We would like to thank Dr. Allison Sylvetsky for her comments on the manuscript.

The publication costs of this article were defrayed in part by the payment of publication fees. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734

Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (http://cebp.aacrjournals.org/).

1.
U.S. Department of Agriculture and U.S. Department of Health and Human Services
.
Dietary Guidelines for Americans, 2020–2025
. 9th Edition;
December 2020
.
Available from
: DietaryGuidelines.gov.
2.
Welsh
JA
,
Sharma
AJ
,
Grellinger
L
,
Vos
MB
.
Consumption of added sugars is decreasing in the United States
.
Am J Clin Nutr
2011
;
94
:
726
34
.
3.
Rosinger
A
,
Herrick
K
,
Gahche
J
,
Park
S
.
Sugar-sweetened beverage consumption among U.S. adults, 2011–2014
.
NCHS Data Brief
2017
:
1
8
.
4.
Marriott
BP
,
Hunt
KJ
,
Malek
AM
,
Newman
JC
.
Trends in intake of energy and total sugar from sugar-sweetened beverages in the United States among children and adults, NHANES 2003–2016
.
Nutrients
2019
;
11
:
2004
.
5.
Sylvetsky
AC
,
Welsh
JA
,
Brown
RJ
,
Vos
MB
.
Low-calorie sweetener consumption is increasing in the United States
.
Am J Clin Nutr
2012
;
96
:
640
6
.
6.
Fakhouri
TH
,
Kit
BK
,
Ogden
CL
.
Consumption of diet drinks in the United States, 20092010
.
NCHS Data Brief
2012
:
1
8
.
7.
Sylvetsky
AC
,
Jin
Y
,
Clark
EJ
,
Welsh
JA
,
Rother
KI
,
Talegawkar
SA
.
Consumption of low-calorie sweeteners among children and adults in the United States
.
J Acad Nutr Diet
2017
;
117
:
441
8
.
8.
World Cancer Research Fund/American Institute for Cancer Research
.
Diet, nutrition, physical activity and cancer: a global perspective
.
Continuous update project expert report 2018. Available from:
dietandcancerreport.org.
9.
World Cancer Research Fund/American Institute for Cancer Research
.
Continuous update project expert report 2018
.
Diet, nutrition and physical activity: energy balance and body fatness. Available from:
dietandcancerreport.org.
10.
Lauby-Secretan
B
,
Scoccianti
C
,
Loomis
D
,
Grosse
Y
,
Bianchini
F
,
Straif
K
, et al
.
Body fatness and cancer–viewpoint of the IARC working group
.
N Engl J Med
2016
;
375
:
794
8
.
11.
Aeberli
I
,
Gerber
PA
,
Hochuli
M
,
Kohler
S
,
Haile
SR
,
Gouni-Berthold
I
, et al
.
Low to moderate sugar-sweetened beverage consumption impairs glucose and lipid metabolism and promotes inflammation in healthy young men: a randomized controlled trial
.
Am J Clin Nutr
2011
;
94
:
479
85
.
12.
Lin
WT
,
Kao
YH
,
Sothern
MS
,
Seal
DW
,
Lee
CH
,
Lin
HY
, et al
.
The association between sugar-sweetened beverages intake, body mass index, and inflammation in US adults
.
Int J Public Health
2020
;
65
:
45
53
.
13.
Odegaard
AO
,
Choh
AC
,
Czerwinski
SA
,
Towne
B
,
Demerath
EW
.
Sugar-sweetened and diet beverages in relation to visceral adipose tissue
.
Obesity (Silver Spring)
2012
;
20
:
689
91
.
14.
Ma
J
,
McKeown
NM
,
Hwang
SJ
,
Hoffmann
U
,
Jacques
PF
,
Fox
CS
.
Sugar-sweetened beverage consumption is associated with change of visceral adipose tissue over 6 years of follow-up
.
Circulation
2016
;
133
:
370
7
.
15.
Makarem
N
,
Bandera
EV
,
Nicholson
JM
,
Parekh
N
.
Consumption of sugars, sugary foods, and sugary beverages in relation to cancer risk: a systematic review of longitudinal studies
.
Annu Rev Nutr
2018
;
38
:
17
39
.
16.
Mattes
RD
,
Popkin
BM
.
Nonnutritive sweetener consumption in humans: effects on appetite and food intake and their putative mechanisms
.
Am J Clin Nutr
2009
;
89
:
1
14
.
17.
Fitch
C
,
Keim
KS
,
Academy of Nutrition and Dietetics
.
Position of the Academy of Nutrition and Dietetics: use of nutritive and nonnutritive sweeteners
.
J Acad Nutr Diet
2012
;
112
:
739
58
.
18.
Lohner
S
,
Toews
I
,
Meerpohl
JJ
.
Health outcomes of non-nutritive sweeteners: analysis of the research landscape
.
Nutr J
2017
;
16
:
55
.
19.
Higgins
KA
,
Mattes
RD
.
A randomized controlled trial contrasting the effects of 4 low-calorie sweeteners and sucrose on body weight in adults with overweight or obesity
.
Am J Clin Nutr
2019
;
109
:
1288
301
.
20.
Bleich
SN
,
Wolfson
JA
,
Vine
S
,
Wang
YC
.
Diet-beverage consumption and caloric intake among US adults, overall and by body weight
.
Am J Public Health
2014
;
104
:
e72
8
.
21.
Suez
J
,
Korem
T
,
Zeevi
D
,
Zilberman-Schapira
G
,
Thaiss
CA
,
Maza
O
, et al
.
Artificial sweeteners induce glucose intolerance by altering the gut microbiota
.
Nature
2014
;
514
:
181
6
.
22.
Palmnas
MS
,
Cowan
TE
,
Bomhof
MR
,
Su
J
,
Reimer
RA
,
Vogel
HJ
, et al
.
Low-dose aspartame consumption differentially affects gut microbiota-host metabolic interactions in the diet-induced obese rat
.
PLoS One
2014
;
9
:
e109841
.
23.
Bian
X
,
Chi
L
,
Gao
B
,
Tu
P
,
Ru
H
,
Lu
K
.
The artificial sweetener acesulfame potassium affects the gut microbiome and body weight gain in CD-1 mice
.
PLoS One
2017
;
12
:
e0178426
.
24.
Bian
X
,
Chi
L
,
Gao
B
,
Tu
P
,
Ru
H
,
Lu
K
.
Gut microbiome response to sucralose and its potential role in inducing liver inflammation in mice
.
Front Physiol
2017
;
8
:
487
.
25.
Ahmad
SY
,
Friel
J
,
Mackay
D
.
The effects of non-nutritive artificial sweeteners, aspartame and sucralose, on the gut microbiome in healthy adults: secondary outcomes of a randomized double-blinded crossover clinical trial
.
Nutrients
2020
;
12
:
3408
.
26.
Dalenberg
JR
,
Patel
BP
,
Denis
R
,
Veldhuizen
MG
,
Nakamura
Y
,
Vinke
PC
, et al
.
Short-term consumption of sucralose with, but not without, carbohydrate impairs neural and metabolic sensitivity to sugar in humans
.
Cell Metab
2020
;
31
:
493
502
.
27.
Sylvetsky
AC
,
Sen
S
,
Merkel
P
,
Dore
F
,
Stern
DB
,
Henry
CJ
, et al
.
Consumption of diet soda sweetened with sucralose and acesulfame-potassium alters inflammatory transcriptome pathways in females with overweight and obesity
.
Mol Nutr Food Res
2020
;
64
:
e1901166
.
28.
Malik
VS
,
Li
Y
,
Pan
A
,
De Koning
L
,
Schernhammer
E
,
Willett
WC
, et al
.
Long-term consumption of sugar-sweetened and artificially sweetened beverages and risk of mortality in US adults
.
Circulation
2019
;
139
:
2113
25
.
29.
Chazelas
E
,
Srour
B
,
Desmetz
E
,
Kesse-Guyot
E
,
Julia
C
,
Deschamps
V
, et al
.
Sugary drink consumption and risk of cancer: results from NutriNet-Sante prospective cohort
.
BMJ
2019
;
366
:
l2408
.
30.
Mullee
A
,
Romaguera
D
,
Pearson-Stuttard
J
,
Viallon
V
,
Stepien
M
,
Freisling
H
, et al
.
Association between soft drink consumption and mortality in 10 european countries
.
JAMA Intern Med
2019
;
179
:
1479
90
.
31.
Odegaard
AO
,
Koh
WP
,
Yuan
JM
,
Pereira
MA
.
Beverage habits and mortality in Chinese adults
.
J Nutr
2015
;
145
:
595
604
.
32.
Zhang
YB
,
Chen
JX
,
Jiang
YW
,
Xia
PF
,
Pan
A
.
Association of sugar-sweetened beverage and artificially sweetened beverage intakes with mortality: an analysis of US national health and nutrition examination survey
.
Eur J Nutr
2021
;
60
:
1945
55
.
33.
Hodge
AM
,
Bassett
JK
,
Milne
RL
,
English
DR
,
Giles
GG
.
Consumption of sugar-sweetened and artificially sweetened soft drinks and risk of obesity-related cancers
.
Public Health Nutr
2018
;
21
:
1618
26
.
34.
Makarem
N
,
Bandera
EV
,
Lin
Y
,
Jacques
PF
,
Hayes
RB
,
Parekh
N
.
Consumption of sugars, sugary foods, and sugary beverages in relation to adiposity-related cancer risk in the framingham offspring cohort (1991–2013)
.
Cancer Prev Res
2018
;
11
:
347
58
.
35.
Debras
C
,
Chazelas
E
,
Srour
B
,
Druesne-Pecollo
N
,
Esseddik
Y
,
Szabo de Edelenyi
F
, et al
.
Artificial sweeteners and cancer risk: results from the NutriNet-Sante population-based cohort study
.
PLoS Med
2022
;
19
:
e1003950
.
36.
Landrigan
PJ
,
Straif
K
.
Aspartame and cancer—new evidence for causation
.
Environ Health
2021
;
20
:
42
.
37.
Llaha
F
,
Gil-Lespinard
M
,
Unal
P
,
de Villasante
I
,
Castaneda
J
,
Zamora-Ros
R
.
Consumption of sweet beverages and cancer risk. a systematic review and meta-analysis of observational studies
.
Nutrients
2021
;
13
:
516
.
38.
Garfinkel
L
.
Selection, follow-up, and analysis in the american cancer society prospective studies
. In:
NCI
,
editor, Monograph 67
.
Washington, DC
:
Government Printing Office
;
1985
. p.
49
52
.
39.
Jacobs
EJ
,
Newton
CC
,
Wang
Y
,
Campbell
PT
,
Flanders
WD
,
Gapstur
SM
.
Ghost-time bias from imperfect mortality ascertainment in aging cohorts
.
Ann Epidemiol
2018
;
28
:
691
6
.
40.
Zhang
X
,
Albanes
D
,
Beeson
WL
,
van den Brandt
PA
,
Buring
JE
,
Flood
A
, et al
.
Risk of colon cancer and coffee, tea, and sugar-sweetened soft drink intake: pooled analysis of prospective cohort studies
.
J Natl Cancer Inst
2010
;
102
:
771
83
.
41.
Pacheco
LS
,
Anderson
CAM
,
Lacey
JV
Jr
,
Giovannucci
EL
,
Lemus
H
,
Araneta
MRG
, et al
.
Sugar-sweetened beverages and colorectal cancer risk in the California teachers study
.
PLoS One
2019
;
14
:
e0223638
.
42.
Hur
J
,
Otegbeye
E
,
Joh
HK
,
Nimptsch
K
,
Ng
K
,
Ogino
S
, et al
.
Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women
.
Gut
2021
;
70
:
2330
6
.
43.
Meyerhardt
JA
,
Sato
K
,
Niedzwiecki
D
,
Ye
C
,
Saltz
LB
,
Mayer
RJ
, et al
.
Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803
.
J Natl Cancer Inst
2012
;
104
:
1702
11
.
44.
Livesey
G
,
Taylor
R
,
Livesey
HF
,
Buyken
AE
,
Jenkins
DJA
,
Augustin
LSA
, et al
.
Dietary glycemic index and load and the risk of type 2 diabetes: assessment of causal relations
.
Nutrients
2019
;
11
:
1436
.
45.
Campbell
PT
.
The role of diabetes and diabetes treatments in colorectal cancer mortality, incidence and survival
.
Curr Nutr Rep
2013
:
37
47
.
46.
Dehal
AN
,
Newton
CC
,
Jacobs
EJ
,
Patel
AV
,
Gapstur
SM
,
Campbell
PT
.
Impact of diabetes mellitus and insulin use on survival after colorectal cancer diagnosis: the cancer prevention study-II nutrition cohort
.
J Clin Oncol
2012
;
30
:
53
9
.
47.
Lee
JE
,
Hunter
DJ
,
Spiegelman
D
,
Adami
HO
,
Bernstein
L
,
van den Brandt
PA
, et al
.
Intakes of coffee, tea, milk, soda and juice and renal cell cancer in a pooled analysis of 13 prospective studies
.
Int J Cancer
2007
;
121
:
2246
53
.
48.
Heath
AK
,
Clasen
JL
,
Jayanth
NP
,
Jenab
M
,
Tjonneland
A
,
Petersen
KEN
, et al
.
Soft drink and juice consumption and renal cell carcinoma incidence and mortality in the european prospective investigation into cancer and nutrition
.
Cancer Epidemiol Biomarkers Prev
2021
;
30
:
1270
4
.
49.
Allen
NE
,
Balkwill
A
,
Beral
V
,
Green
J
,
Reeves
G
,
Collaborators MWS
.
Fluid intake and incidence of renal cell carcinoma in UK women
.
Br J Cancer
2011
;
104
:
1487
92
.
50.
Smith
TJ
,
Wolfson
JA
,
Jiao
D
,
Crupain
MJ
,
Rangan
U
,
Sapkota
A
, et al
.
Caramel color in soft drinks and exposure to 4-methylimidazole: a quantitative risk assessment
.
PLoS One
2015
;
10
:
e0118138
.
51.
International Agency for Research on Cancer
.
4-Methylimidazole. Some chemicals present in industrial and consumer products, food and drinking-water
.
Int Agency Res Cancer
2013
;
101
:
447
59
.
52.
Muncke
J
.
Endocrine disrupting chemicals and other substances of concern in food contact materials: an updated review of exposure, effect and risk assessment
.
J Steroid Biochem Mol Biol
2011
;
127
:
118
27
.
53.
Sylvetsky
AC
,
Rother
KI
.
Trends in the consumption of low-calorie sweeteners
.
Physiol Behav
2016
;
164
(
Pt B
):
446
50
.
54.
Campbell
PT
,
Newton
CC
,
Patel
AV
,
Jacobs
EJ
,
Gapstur
SM
.
Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults
.
Diabetes Care
2012
;
35
:
1835
44
.
55.
Giovannucci
E
,
Harlan
DM
,
Archer
MC
,
Bergenstal
RM
,
Gapstur
SM
,
Habel
LA
, et al
.
Diabetes and cancer: a consensus report
.
CA Cancer J Clin
2010
;
60
:
207
21
.
56.
Genkinger
JM
,
Kitahara
CM
,
Bernstein
L
,
Berrington de Gonzalez
A
,
Brotzman
M
,
Elena
JW
, et al
.
Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies
.
Ann Oncol
2015
;
26
:
2257
66
.
57.
Navarrete-Munoz
EM
,
Wark
PA
,
Romaguera
D
,
Bhoo-Pathy
N
,
Michaud
D
,
Molina-Montes
E
, et al
.
Sweet-beverage consumption and risk of pancreatic cancer in the european prospective investigation into cancer and nutrition (EPIC)
.
Am J Clin Nutr
2016
;
104
:
760
8
.
58.
Schernhammer
ES
,
Hu
FB
,
Giovannucci
E
,
Michaud
DS
,
Colditz
GA
,
Stampfer
MJ
, et al
.
Sugar-sweetened soft drink consumption and risk of pancreatic cancer in two prospective cohorts
.
Cancer Epidemiol Biomarker Prev
2005
;
14
:
2098
105
.
59.
Bao
Y
,
Stolzenberg-Solomon
R
,
Jiao
L
,
Silverman
DT
,
Subar
AF
,
Park
Y
, et al
.
Added sugar and sugar-sweetened foods and beverages and the risk of pancreatic cancer in the national institutes of health-AARP diet and health study
.
Am J Clin Nutr
2008
;
88
:
431
40
.
60.
Dunford
EK
,
Miles
DR
,
Ng
SW
,
Popkin
B
.
Types and amounts of nonnutritive sweeteners purchased by US households: a comparison of 2002 and 2018 nielsen homescan purchases
.
J Acad Nutr Diet
2020
;
120
:
1662
71
.

Supplementary data